Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Peter Carroll, MD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentUrology
    Address550 16th Street, 6th Floor
    San Francisco CA 94143
    Phone415-353-7098
      Other Positions
      TitleChair, Urology


       Biography 
       Education and Training
      University of California, San FranciscoResidency School of Medicine -Urology

       ORNG Applications 
       Websites
       In The News
       Awarded Grants

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Bangma CH, Valdagni R, Carroll PR, van Poppel H, Klotz L, Hugosson J. Active Surveillance for Low-risk Prostate Cancer: Developments to Date. Eur Urol. 2015 Apr; 67(4):646-8.
        View in: PubMed
      2. Xia J, Trock BJ, Gulati R, Mallinger L, Cooperberg MR, Carroll PR, Carter HB, Etzioni R. Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics. Clin Cancer Res. 2014 Oct 15; 20(20):5302-10.
        View in: PubMed PMC4203422
      3. Gerstenberger JP, Bauer SR, Van Blarigan EL, Sosa E, Song X, Witte JS, Carroll PR, Chan JM. Selenoprotein and antioxidant genes and the risk of high-grade prostate cancer and prostate cancer recurrence. Prostate. 2015 Jan; 75(1):60-9.
        View in: PubMed PMC4257852
      4. Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, Chan JM, Meng MV, Simko JP, Cooperberg MR, Carroll PR. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol. 2015 Mar; 193(3):807-11.
        View in: PubMed
      5. Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, Small EJ. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014 Nov; 106(11).
        View in: PubMed PMC4241888
      6. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014 Sep; 12(9):1211-9; quiz 1219.
        View in: PubMed
      7. Klein EA, Cooperberg MR, Carroll PR. Reply to Yuri Tolkach, Markus Kuczyk, Florian Imkamp's Letter to the Editor re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. Eur Urol 2014;66:550-60. Eur Urol. 2014 Dec; 66(6):e117-8.
        View in: PubMed
      8. Wang SY, Shiboski S, Belair CD, Cooperberg MR, Simko JP, Stoppler H, Cowan J, Carroll PR, Blelloch R. miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance. PLoS One. 2014; 9(6):e98597.
        View in: PubMed PMC4043973
      9. Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014 Sep; 66(3):550-60.
        View in: PubMed
      10. Porten SP, Smith A, Odisho AY, Litwin MS, Saigal CS, Carroll PR, Cooperberg MR. Updated trends in imaging use in men diagnosed with prostate cancer. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):246-51.
        View in: PubMed
      11. Welty CJ, Cooperberg MR, Carroll PR. Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer. Curr Opin Urol. 2014 May; 24(3):288-92.
        View in: PubMed
      12. Carroll PR, Vickers AJ. Point/Counterpoint: early detection of prostate cancer: do the benefits outweigh the consequences? J Natl Compr Canc Netw. 2014 May; 12(5 Suppl):768-71.
        View in: PubMed
      13. Greene KL, Punnen S, Carroll PR. Evolution and immediate future of US screening guidelines. Urol Clin North Am. 2014 May; 41(2):229-35.
        View in: PubMed
      14. Jalloh M, Myers F, Cowan JE, Carroll PR, Cooperberg MR. Racial Variation in Prostate Cancer Upgrading and Upstaging Among Men with Low-risk Clinical Characteristics. Eur Urol. 2015 Mar; 67(3):451-7.
        View in: PubMed
      15. Jarow JP, Thompson IM, Kluetz PG, Baxley J, Sridhara R, Scardino P, Carroll P, Albertsen P, Carter HB, Brawley O, Sartor O, Sandler H, Kiefert JJ, Morton RA. Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshop. Urology. 2014 May; 83(5):975-8.
        View in: PubMed
      16. Morgan TM, Meng MV, Cooperberg MR, Cowan JE, Weinberg V, Carroll PR, Lin DW. A risk-adjusted definition of biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2014 Jun; 17(2):174-9.
        View in: PubMed
      17. Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M, Carroll PR. Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes. PLoS One. 2014; 9(3):e89754.
        View in: PubMed PMC3940667
      18. Vickers AJ, Thompson IM, Klein E, Carroll PR, Scardino PT. A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer. Urology. 2014 Mar; 83(3):592-6.
        View in: PubMed
      19. Bennett A, Gnjidic D, Gillett M, Carroll P, Matthews S, Johnell K, Fastbom J, Hilmer S. Prevalence and impact of fall-risk-increasing drugs, polypharmacy, and drug-drug interactions in robust versus frail hospitalised falls patients: a prospective cohort study. Drugs Aging. 2014 Mar; 31(3):225-32.
        View in: PubMed
      20. Welty CJ, Carroll PR. The ongoing need for improved risk stratification and monitoring for those on active surveillance for early stage prostate cancer. Eur Urol. 2014 Jun; 65(6):1032-3.
        View in: PubMed
      21. Brajtbord JS, Punnen S, Cowan JE, Welty CJ, Carroll PR. Age and baseline quality of life at radical prostatectomy--who has the most to lose? J Urol. 2014 Aug; 192(2):396-401.
        View in: PubMed
      22. Wang SY, Cowan JE, Cary KC, Chan JM, Carroll PR, Cooperberg MR. Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. BJU Int. 2014 Dec; 114(6b):E18-24.
        View in: PubMed
      23. Johnston C, Hilmer SN, McLachlan AJ, Matthews ST, Carroll PR, Kirkpatrick CM. The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration. Eur J Clin Pharmacol. 2014 May; 70(5):549-55.
        View in: PubMed
      24. Magbanua MJ, Richman EL, Sosa EV, Jones LW, Simko J, Shinohara K, Haqq CM, Carroll PR, Chan JM. Physical activity and prostate gene expression in men with low-risk prostate cancer. Cancer Causes Control. 2014 Apr; 25(4):515-23.
        View in: PubMed PMC3990413
      25. Anwar M, Westphalen AC, Jung AJ, Noworolski SM, Simko JP, Kurhanewicz J, Roach M, Carroll PR, Coakley FV. Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: quantitative analysis of imaging contour compared to whole-mount histopathology. Radiother Oncol. 2014 Feb; 110(2):303-8.
        View in: PubMed PMC3969841
      26. Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014 Jun; 65(6):1046-55.
        View in: PubMed PMC4113338
      27. Glass AS, Hilton JF, Cowan JE, Washington SL, Carroll PR. Serial prostate biopsy and risk of lower urinary tract symptoms: results from a large, single-institution active surveillance cohort. Urology. 2014 Jan; 83(1):33-8.
        View in: PubMed
      28. Jung AJ, Westphalen AC, Kurhanewicz J, Wang ZJ, Carroll PR, Simko JP, Coakley FV. Clinical utility of endorectal MRI-guided prostate biopsy: preliminary experience. J Magn Reson Imaging. 2014 Aug; 40(2):314-23.
        View in: PubMed PMC4059791
      29. Cary KC, Singla N, Cowan JE, Carroll PR, Cooperberg MR. Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer: analysis from the CaPSURE™ registry. J Urol. 2014 Apr; 191(4):964-70.
        View in: PubMed
      30. Cary KC, Paciorek A, Fuldeore MJ, Carroll PR, Cooperberg MR. Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy: an analysis from the CaPSURE registry. Cancer. 2014 Feb 15; 120(4):507-12.
        View in: PubMed
      31. Starobinets O, Guo R, Simko JP, Kuchinsky K, Kurhanewicz J, Carroll PR, Greene KL, Noworolski SM. Semiautomatic registration of digital histopathology images to in vivo MR images in molded and unmolded prostates. J Magn Reson Imaging. 2014 May; 39(5):1223-9.
        View in: PubMed PMC3984354
      32. Tomaszewski JJ, Richman EL, Sadetsky N, O'Keefe DS, Carroll PR, Davies BJ, Chan JM. Impact of folate intake on prostate cancer recurrence following definitive therapy: data from CaPSURE™. J Urol. 2014 Apr; 191(4):971-6.
        View in: PubMed
      33. Ornish D, Lin J, Chan JM, Epel E, Kemp C, Weidner G, Marlin R, Frenda SJ, Magbanua MJ, Daubenmier J, Estay I, Hills NK, Chainani-Wu N, Carroll PR, Blackburn EH. Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. Lancet Oncol. 2013 Oct; 14(11):1112-20.
        View in: PubMed
      34. Cary KC, Cowan JE, Sanford M, Shinohara K, Perez N, Chan JM, Meng MV, Carroll PR. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies. Eur Urol. 2014 Aug; 66(2):337-42.
        View in: PubMed
      35. Bauer SR, Richman EL, Sosa E, Weinberg V, Song X, Witte JS, Carroll PR, Chan JM. Antioxidant and vitamin E transport genes and risk of high-grade prostate cancer and prostate cancer recurrence. Prostate. 2013 Dec; 73(16):1786-95.
        View in: PubMed
      36. Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S, van Poppel H, Roach M, Stephenson A, Wiegel T, Zelefsky MJ. Early salvage radiotherapy following radical prostatectomy. Eur Urol. 2014 Jun; 65(6):1034-43.
        View in: PubMed
      37. Broering JM, Paciorek A, Carroll PR, Wilson LS, Litwin MS, Miaskowski C. Measurement equivalence using a mixed-mode approach to administer health-related quality of life instruments. Qual Life Res. 2014 Mar; 23(2):495-508.
        View in: PubMed
      38. Cooperberg MR, Cowan JE, Carroll PR. Reply to A. Azad et al. J Clin Oncol. 2013 Sep 10; 31(26):3296-7.
        View in: PubMed
      39. Cary KC, Carroll PR. Editorial comment. J Urol. 2013 Oct; 190(4):1223.
        View in: PubMed
      40. Punnen S, Cowan JE, Dunn LB, Shumay DM, Carroll PR, Cooperberg MR. A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU Int. 2013 Jul; 112(2):E67-75.
        View in: PubMed
      41. Akaza H, Hinotsu S, Cooperberg MR, Chung BH, Youl Lee J, Umbas R, Tsukamoto T, Namiki M, Carroll P. Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes. Jpn J Clin Oncol. 2013 Jul; 43(7):756-66.
        View in: PubMed
      42. Glass AS, Cowan JE, Fuldeore MJ, Cooperberg MR, Carroll PR, Kenfield SA, Greene KL. Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era. Urology. 2013 Jul; 82(1):60-5.
        View in: PubMed
      43. Chang ST, Westphalen AC, Jha P, Jung AJ, Carroll PR, Kurhanewicz J, Coakley FV. Endorectal MRI and MR spectroscopic imaging of prostate cancer: developing selection criteria for MR-guided focal therapy. J Magn Reson Imaging. 2014 Mar; 39(3):519-25.
        View in: PubMed PMC3748229
      44. Punnen S, Freedland SJ, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Carroll PR, Cooperberg MR. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Eur Urol. 2014 Jun; 65(6):1171-7.
        View in: PubMed
      45. Odisho AY, Washington SL, Meng MV, Cowan JE, Simko JP, Carroll PR. Benign prostate glandular tissue at radical prostatectomy surgical margins. Urology. 2013 Jul; 82(1):154-9.
        View in: PubMed PMC3696410
      46. Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z, Gleave ME, Lance RS, Sanda MG, Thompson IM, Wei JT, Nelson PS. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res. 2013 May 1; 19(9):2442-50.
        View in: PubMed PMC3674574
      47. Punnen S, Meng MV, Cooperberg MR, Greene KL, Cowan JE, Carroll PR. How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer? BJU Int. 2013 Aug; 112(4):E314-20.
        View in: PubMed
      48. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS, Swanson GP, Stone S, Carroll PR. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013 Apr 10; 31(11):1428-34.
        View in: PubMed
      49. Harris CR, Punnen S, Carroll PR. Men with low preoperative sexual function may benefit from nerve sparing radical prostatectomy. J Urol. 2013 Sep; 190(3):981-6.
        View in: PubMed
      50. Glass AS, Porten SP, Bonham M, Tran TC, Cowan JE, Punnen S, Chan JM, Carroll PR. Active surveillance: does serial prostate biopsy increase histological inflammation? Prostate Cancer Prostatic Dis. 2013 Jun; 16(2):165-9.
        View in: PubMed
      51. Glass AS, Carroll PR. Focal therapy: a new active surveillance tool? Oncology (Williston Park). 2013 Jan 15; 27(1).
        View in: PubMed
      52. Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M, Hernandez J, Hurtado-Coll A, Kuchinsky K, Liew J, Mendez-Meza R, Smith E, Tenggara I, Zhang X, Carroll PR, Chan JM, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, Feng Z, True LD, Brooks JD. A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. Adv Anat Pathol. 2013 Jan; 20(1):39-44.
        View in: PubMed PMC3535290
      53. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. J Urol. 2013 Jan; 189(1 Suppl):S2-S11.
        View in: PubMed
      54. Glass AS, Cooperberg MR, Meng MV, Carroll PR. Role of active surveillance in the management of localized prostate cancer. J Natl Cancer Inst Monogr. 2012 Dec; 2012(45):202-6.
        View in: PubMed PMC3540869
      55. Eastham JA, Carroll P, Pisters L, Nguyen PT, Touijer K. Salvage therapies after radiation therapy. Urol Oncol. 2012 Nov-Dec; 30(6):940-1.
        View in: PubMed
      56. Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter HB, Etzioni R. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res. 2012 Oct 1; 18(19):5471-8.
        View in: PubMed PMC3604990
      57. Resnick MJ, Guzzo TJ, Cowan JE, Knight SJ, Carroll PR, Penson DF. Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int. 2013 Feb; 111(2):213-20.
        View in: PubMed PMC3540193
      58. Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012 Oct 1; 30(28):3540-4.
        View in: PubMed PMC3454771
      59. Odisho AY, Berry AB, Ahmad AE, Cooperberg MR, Carroll PR, Konety BR. Reply to Jai Prakash, Apul Goel and Manish Garg's Letter to the Editor re: Anobel Y. Odisho, Anna B. Berry, Ardalan E. Ahmad, Matthew R. Cooperberg, Peter R. Carroll, Badrinath R. Konety. Reflex ImmunoCyt Testing for the Diagnosis of Bladder Cancer in Patients with Atypical Urine Cytology. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.04.019. Eur Urol. 2012 Nov; 62(5):e88.
        View in: PubMed
      60. Yang G, Villalta JD, Weiss DA, Carroll PR, Breyer BN. Gender differences in academic productivity and academic career choice among urology residents. J Urol. 2012 Oct; 188(4):1286-90.
        View in: PubMed PMC3552430
      61. Hilton JF, Blaschko SD, Whitson JM, Cowan JE, Carroll PR. The impact of serial prostate biopsies on sexual function in men on active surveillance for prostate cancer. J Urol. 2012 Oct; 188(4):1252-8.
        View in: PubMed
      62. Bangma CH, Bul M, van der Kwast TH, Pickles T, Korfage IJ, Hoeks CM, Steyerberg EW, Jenster G, Kattan MW, Bellardita L, Carroll PR, Denis LJ, Parker C, Roobol MJ, Emberton M, Klotz LH, Rannikko A, Kakehi Y, Lane JA, Schröder FH, Semjonow A, Trock BJ, Valdagni R. Active surveillance for low-risk prostate cancer. Crit Rev Oncol Hematol. 2013 Mar; 85(3):295-302.
        View in: PubMed
      63. Cummins NM, Jakeman PM, Sestak I, Murphy N, Carroll P. The effect of behavioural risk factors on osteoporosis in Irish women. Ir J Med Sci. 2013 Mar; 182(1):97-105.
        View in: PubMed
      64. Glass AS, Cooperberg MR, Carroll PR. Early detection of prostate cancer: more information, more clarity. Eur Urol. 2012 Nov; 62(5):753-5; discussion 755-6.
        View in: PubMed
      65. Kutikov A, Cooperberg MR, Paciorek AT, Uzzo RG, Carroll PR, Boorjian SA. Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram. Prostate Cancer Prostatic Dis. 2012 Dec; 15(4):374-9.
        View in: PubMed PMC3815610
      66. Jung AJ, Coakley FV, Shinohara K, Carroll PR, Kurhanewicz J, Cowan JE, Westphalen AC. Local staging of prostate cancer: comparative accuracy of T2-weighted endorectal MR imaging and transrectal ultrasound. Clin Imaging. 2012 Sep-Oct; 36(5):547-52.
        View in: PubMed PMC3694423
      67. Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012 Dec; 62(6):976-83.
        View in: PubMed
      68. Montorsi F, Wilson TG, Rosen RC, Ahlering TE, Artibani W, Carroll PR, Costello A, Eastham JA, Ficarra V, Guazzoni G, Menon M, Novara G, Patel VR, Stolzenburg JU, Van der Poel H, Van Poppel H, Mottrie A. Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol. 2012 Sep; 62(3):368-81.
        View in: PubMed
      69. Reese AC, Cowan JE, Brajtbord JS, Harris CR, Carroll PR, Cooperberg MR. The quantitative Gleason score improves prostate cancer risk assessment. Cancer. 2012 Dec 15; 118(24):6046-54.
        View in: PubMed
      70. Novara G, Ficarra V, Mocellin S, Ahlering TE, Carroll PR, Graefen M, Guazzoni G, Menon M, Patel VR, Shariat SF, Tewari AK, Van Poppel H, Zattoni F, Montorsi F, Mottrie A, Rosen RC, Wilson TG. Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol. 2012 Sep; 62(3):382-404.
        View in: PubMed
      71. Ficarra V, Novara G, Rosen RC, Artibani W, Carroll PR, Costello A, Menon M, Montorsi F, Patel VR, Stolzenburg JU, Van der Poel H, Wilson TG, Zattoni F, Mottrie A. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol. 2012 Sep; 62(3):405-17.
        View in: PubMed
      72. Hayes GM, Simko J, Holochwost D, Kuchinsky K, Busch R, Misell L, Murphy EJ, Carroll P, Chan J, Shinohara K, Hellerstein MK. Regional cell proliferation in microdissected human prostate specimens after heavy water labeling in vivo: correlation with prostate epithelial cells isolated from seminal fluid. Clin Cancer Res. 2012 Jun 15; 18(12):3250-60.
        View in: PubMed
      73. Kane A, Mitchell SJ, Carroll PR, Matthews S, Hilmer SN. Characteristics of older and younger patients with suspected paracetamol toxicity. Australas J Ageing. 2012 Sep; 31(3):190-3.
        View in: PubMed
      74. Odisho AY, Berry AB, Ahmad AE, Cooperberg MR, Carroll PR, Konety BR. Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology. Eur Urol. 2013 May; 63(5):936-40.
        View in: PubMed PMC3443544
      75. Berglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, deVere White R, Hemstreet GP, Crawford ED, Thompson IM, Klein EA. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology. 2012 Mar; 79(3):633-7.
        View in: PubMed PMC3839235
      76. Aaronson DS, Odisho AY, Hills N, Cress R, Carroll PR, Dudley RA, Cooperberg MR. Proton beam therapy and treatment for localized prostate cancer: if you build it, they will come. Arch Intern Med. 2012 Feb 13; 172(3):280-3.
        View in: PubMed
      77. Arrayeh E, Westphalen AC, Kurhanewicz J, Roach M, Jung AJ, Carroll PR, Coakley FV. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys. 2012 Apr 1; 82(5):e787-93.
        View in: PubMed PMC3285390
      78. Akaza H, Carroll P, Cooperberg MR, Hinotsu S. Fifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management. Jpn J Clin Oncol. 2012 Mar; 42(3):226-36.
        View in: PubMed
      79. Cooperberg MR, Odisho AY, Carroll PR. Outcomes for radical prostatectomy: is it the singer, the song, or both? J Clin Oncol. 2012 Feb 10; 30(5):476-8.
        View in: PubMed
      80. Messing EM, Albertsen P, Andriole GL, Carroll PR, Klein EA. The Society of Urologic Oncology's reply to the US Preventative Services Task Force's recommendation on PSA testing. Urol Oncol. 2012 Jan-Feb; 30(1):117-9.
        View in: PubMed
      81. Muglia VF, Westphalen AC, Wang ZJ, Kurhanewicz J, Carroll PR, Coakley FV. Endorectal MRI of prostate cancer: incremental prognostic importance of gross locally advanced disease. AJR Am J Roentgenol. 2011 Dec; 197(6):1369-74.
        View in: PubMed PMC3703946
      82. Tasian GE, Cooperberg MR, Potter MB, Cowan JE, Greene KL, Carroll PR, Chan JM. PSA screening: determinants of primary-care physician practice patterns. Prostate Cancer Prostatic Dis. 2012 Jun; 15(2):189-94.
        View in: PubMed
      83. Washington SL, Bonham M, Whitson JM, Cowan JE, Carroll PR. Transrectal ultrasonography-guided biopsy does not reliably identify dominant cancer location in men with low-risk prostate cancer. BJU Int. 2012 Jul; 110(1):50-5.
        View in: PubMed
      84. Reese AC, Fradet V, Whitson JM, Davis CB, Carroll PR. Poor agreement of prostate specific antigen doubling times calculated using ultrasensitive versus standard prostate specific antigen values: important impact on risk assessment. J Urol. 2011 Dec; 186(6):2228-32.
        View in: PubMed
      85. Punnen S, Cooperberg MR, Sadetsky N, Carroll PR. Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores? BJU Int. 2012 May; 109(10):1520-4.
        View in: PubMed PMC3288727
      86. Porten SP, Whitson JM, Cowan JE, Perez N, Shinohara K, Carroll PR. Changes in cancer volume in serial biopsies of men on active surveillance for early stage prostate cancer. J Urol. 2011 Nov; 186(5):1825-9.
        View in: PubMed
      87. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011 Sep 21; 306(11):1205-14.
        View in: PubMed PMC3831607
      88. Magbanua MJ, Roy R, Sosa EV, Weinberg V, Federman S, Mattie MD, Hughes-Fulford M, Simko J, Shinohara K, Haqq CM, Carroll PR, Chan JM. Gene expression and biological pathways in tissue of men with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation. PLoS One. 2011; 6(9):e24004.
        View in: PubMed PMC3164676
      89. Richman EL, Carroll PR, Chan JM. Vegetable and fruit intake after diagnosis and risk of prostate cancer progression. Int J Cancer. 2012 Jul 1; 131(1):201-10.
        View in: PubMed PMC3310254
      90. Punnen S, Cooperberg MR, Sadetsky N, Carroll PR. Androgen deprivation therapy and cardiovascular risk. J Clin Oncol. 2011 Sep 10; 29(26):3510-6.
        View in: PubMed PMC3179251
      91. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol. 2011 Sep 20; 29(27):3669-76.
        View in: PubMed
      92. McKenney JK, Simko J, Bonham M, True LD, Troyer D, Hawley S, Newcomb LF, Fazli L, Kunju LP, Nicolas MM, Vakar-Lopez F, Zhang X, Carroll PR, Brooks JD. The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study. J Urol. 2011 Aug; 186(2):465-9.
        View in: PubMed
      93. Cooperberg MR, Mallin K, Kane CJ, Carroll PR. Treatment trends for stage I renal cell carcinoma. J Urol. 2011 Aug; 186(2):394-9.
        View in: PubMed
      94. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011 Nov 15; 117(22):5039-46.
        View in: PubMed PMC3170662
      95. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol. 2011 Jul 10; 29(20):2795-800.
        View in: PubMed
      96. Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res. 2011 Jun 1; 71(11):3889-95.
        View in: PubMed PMC3107352
      97. Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, Bjartell AS, Montorsi F, Freedland SJ, Erbersdobler A, van der Kwast TH. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol. 2011 Aug; 60(2):291-303.
        View in: PubMed
      98. Whitson JM, Porten SP, Cowan JE, Simko JP, Cooperberg MR, Carroll PR. Factors associated with downgrading in patients with high grade prostate cancer. Urol Oncol. 2013 May; 31(4):442-7.
        View in: PubMed
      99. Carroll PR, Whitson JM. Editorial comment. Urology. 2011 Apr; 77(4):984-5.
        View in: PubMed
      100. Dall'Era MA, Cowan JE, Simko J, Shinohara K, Davies B, Konety BR, Meng MV, Perez N, Greene K, Carroll PR. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Int. 2011 Apr; 107(8):1232-7.
        View in: PubMed
      101. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol. 2011 May; 185(5):1656-60.
        View in: PubMed
      102. Mallin K, David KA, Carroll PR, Milowsky MI, Nanus DM. Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). J Urol. 2011 May; 185(5):1631-6.
        View in: PubMed
      103. Sadetsky N, Greene K, Cooperberg MR, Hubbard A, Carroll PR, Satariano W. Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry. Cancer. 2011 Oct 1; 117(19):4406-13.
        View in: PubMed
      104. Porten SP, Cooperberg MR, Konety BR, Carroll PR. The example of CaPSURE: lessons learned from a national disease registry. World J Urol. 2011 Jun; 29(3):265-71.
        View in: PubMed PMC3099175
      105. Whitson JM, Porten SP, Carroll PR. Prostate cancer: reducing overtreatment: active surveillance in low-risk disease. Nat Rev Urol. 2011 Mar; 8(3):124-5.
        View in: PubMed
      106. Kazer MW, Bailey DE, Colberg J, Kelly WK, Carroll P. The needs for men undergoing active surveillance (AS) for prostate cancer: results of a focus group study. J Clin Nurs. 2011 Feb; 20(3-4):581-6.
        View in: PubMed
      107. Hilmer SN, Tran K, Rubie P, Wright J, Gnjidic D, Mitchell SJ, Matthews S, Carroll PR. Gentamicin pharmacokinetics in old age and frailty. Br J Clin Pharmacol. 2011 Feb; 71(2):224-31.
        View in: PubMed PMC3040542
      108. Yang G, Whitson JM, Breyer BN, Konety BR, Carroll PR. Oncological and functional outcomes of radical cystectomy and orthotopic bladder replacement in women. Urology. 2011 Apr; 77(4):878-83.
        View in: PubMed PMC3607667
      109. Carroll PR, Whitson JM, Cooperberg MR. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes? J Clin Oncol. 2011 Feb 1; 29(4):345-7.
        View in: PubMed
      110. Yang G, Zaid UB, Erickson BA, Blaschko SD, Carroll PR, Breyer BN. Urology resident publication output and its relationship to future academic achievement. J Urol. 2011 Feb; 185(2):642-6.
        View in: PubMed PMC3565588
      111. Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. 2011 Jan 10; 29(2):235-41.
        View in: PubMed PMC3058279
      112. Breyer BN, Davis CB, Cowan JE, Kane CJ, Carroll PR. Incidence of bladder neck contracture after robot-assisted laparoscopic and open radical prostatectomy. BJU Int. 2010 Dec; 106(11):1734-8.
        View in: PubMed PMC3565608
      113. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll PR. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol. 2011 Jan 10; 29(2):228-34.
        View in: PubMed PMC3058278
      114. Reese AC, Sadetsky N, Carroll PR, Cooperberg MR. Inaccuracies in assignment of clinical stage for localized prostate cancer. Cancer. 2011 Jan 15; 117(2):283-9.
        View in: PubMed
      115. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stöppler H, Simko J, Hilton JF, Carroll P, Blelloch R. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 2011 Jan 15; 71(2):550-60.
        View in: PubMed PMC3022112
      116. Chan JM, Weinberg V, Magbanua MJ, Sosa E, Simko J, Shinohara K, Federman S, Mattie M, Hughes-Fulford M, Haqq C, Carroll PR. Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer. Cancer Causes Control. 2011 Jan; 22(1):141-50.
        View in: PubMed PMC3002170
      117. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010 Nov 15; 116(22):5226-34.
        View in: PubMed PMC2975879
      118. Porten SP, Richardson DA, Odisho AY, McAninch JW, Carroll PR, Cooperberg MR. Disproportionate presentation of high risk prostate cancer in a safety net health system. J Urol. 2010 Nov; 184(5):1931-6.
        View in: PubMed
      119. Katz MS, Carroll PR, Cowan JE, Chan JM, D'Amico AV. Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU Int. 2010 Sep; 106(5):627-32.
        View in: PubMed
      120. Tasian GE, Cooperberg MR, Cowan JE, Keyashian K, Greene KL, Daniels NA, Carroll PR, Chan JM. Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians. Urol Oncol. 2012 Mar-Apr; 30(2):155-60.
        View in: PubMed
      121. Vickers AJ, Salz T, Basch E, Cooperberg MR, Carroll PR, Tighe F, Eastham J, Rosen RC. Electronic patient self-assessment and management (SAM): a novel framework for cancer survivorship. BMC Med Inform Decis Mak. 2010; 10:34.
        View in: PubMed PMC2893444
      122. Fradet V, Kurhanewicz J, Cowan JE, Karl A, Coakley FV, Shinohara K, Carroll PR. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology. 2010 Jul; 256(1):176-83.
        View in: PubMed PMC2897693
      123. Reese AC, Cooperberg MR, Carroll PR. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease. J Urol. 2010 Jul; 184(1):114-9.
        View in: PubMed
      124. Whitson JM, Carroll PR. Active surveillance for early-stage prostate cancer: defining the triggers for intervention. J Clin Oncol. 2010 Jun 10; 28(17):2807-9.
        View in: PubMed
      125. Walsh TJ, Schembri M, Turek PJ, Chan JM, Carroll PR, Smith JF, Eisenberg ML, Van Den Eeden SK, Croughan MS. Increased risk of high-grade prostate cancer among infertile men. Cancer. 2010 May 1; 116(9):2140-7.
        View in: PubMed PMC2893877
      126. Odisho AY, Cooperberg MR, Fradet V, Ahmad AE, Carroll PR. Urologist density and county-level urologic cancer mortality. J Clin Oncol. 2010 May 20; 28(15):2499-504.
        View in: PubMed PMC2881728
      127. Fang AC, Ahmad AE, Whitson JM, Ferrell LD, Carroll PR, Konety BR. Effect of a minimum lymph node policy in radical cystectomy and pelvic lymphadenectomy on lymph node yields, lymph node positivity rates, lymph node density, and survivorship in patients with bladder cancer. Cancer. 2010 Apr 15; 116(8):1901-8.
        View in: PubMed
      128. Katz MS, Efstathiou JA, D'Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman AL. The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int. 2010 May; 105(10):1417-22.
        View in: PubMed PMC3090683
      129. Healy LA, Ryan AM, Carroll P, Ennis D, Crowley V, Boyle T, Kennedy MJ, Connolly E, Reynolds JV. Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol). 2010 May; 22(4):281-8.
        View in: PubMed
      130. Le JD, Cooperberg MR, Sadetsky N, Hittelman AB, Meng MV, Cowan JE, Latini DM, Carroll PR. Changes in specific domains of sexual function and sexual bother after radical prostatectomy. BJU Int. 2010 Oct; 106(7):1022-9.
        View in: PubMed
      131. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010 Mar 1; 28(7):1117-23.
        View in: PubMed PMC2834465
      132. Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll PR, Carter HB, Catalona WJ, Cookson MS, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP, Howe RJ, Lange PH, Lilja H, Loughlin KR, Mohler J, Moul J, Nadler RB, Patterson SG, Presti JC, Stroup AM, Wake R, Wei JT. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw. 2010 Feb; 8(2):240-62.
        View in: PubMed
      133. Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol. 2010 Feb 20; 28(6):1069-74.
        View in: PubMed PMC2834431
      134. Smaldone MC, Cowan JE, Carroll PR, Davies BJ. Eligibility for active surveillance and pathological outcomes for men undergoing radical prostatectomy in a large, community based cohort. J Urol. 2010 Jan; 183(1):138-43.
        View in: PubMed
      135. Doyle SM, Kahn JG, Hosang N, Carroll PR. The impact of male circumcision on HIV transmission. J Urol. 2010 Jan; 183(1):21-6.
        View in: PubMed
      136. Richman EL, Stampfer MJ, Paciorek A, Broering JM, Carroll PR, Chan JM. Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression. Am J Clin Nutr. 2010 Mar; 91(3):712-21.
        View in: PubMed PMC3132069
      137. Santos CF, Kurhanewicz J, Tabatabai ZL, Simko JP, Keshari KR, Gbegnon A, Santos RD, Federman S, Shinohara K, Carroll PR, Haqq CM, Swanson MG. Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy. NMR Biomed. 2010 May; 23(4):391-8.
        View in: PubMed PMC2891902
      138. Paris PL, Weinberg V, Albo G, Roy R, Burke C, Simko J, Carroll P, Collins C. A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer. Clin Cancer Res. 2010 Jan 1; 16(1):195-202.
        View in: PubMed PMC2854027
      139. Carroll PR. Editorial comment. J Urol. 2010 Feb; 183(2):564.
        View in: PubMed
      140. Aaronson D, Cowan J, Carroll P, Konety B. Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE. BJU Int. 2010 Apr; 105(7):951-5.
        View in: PubMed
      141. Eisenberg ML, Cowan JE, Carroll PR, Shinohara K. The adjunctive use of power Doppler imaging in the preoperative assessment of prostate cancer. BJU Int. 2010 May; 105(9):1237-41.
        View in: PubMed
      142. Whitson JM, Berry AB, Carroll PR, Konety BR. UroVysion testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer. Int Braz J Urol. 2009 Nov-Dec; 35(6):664-70; discussion 671-2.
        View in: PubMed
      143. Lin GA, Aaronson DS, Knight SJ, Carroll PR, Dudley RA. Patient decision aids for prostate cancer treatment: a systematic review of the literature. CA Cancer J Clin. 2009 Nov-Dec; 59(6):379-90.
        View in: PubMed
      144. Abouassaly R, Paciorek A, Ryan CJ, Carroll PR, Klein EA. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE. Cancer. 2009 Oct 1; 115(19):4470-6.
        View in: PubMed
      145. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009 Nov; 182(5):2232-41.
        View in: PubMed
      146. Bailey DE, Wallace M, Latini DM, Hegarty J, Carroll PR, Klein EA, Albertsen PC. Measuring illness uncertainty in men undergoing active surveillance for prostate cancer. Appl Nurs Res. 2011 Nov; 24(4):193-9.
        View in: PubMed PMC3070758
      147. Newcomb LF, Brooks JD, Carroll PR, Feng Z, Gleave ME, Nelson PS, Thompson IM, Lin DW. Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology. 2010 Feb; 75(2):407-13.
        View in: PubMed PMC3827723
      148. Sadetsky N, Hubbard A, Carroll PR, Satariano W. Predictive value of serial measurements of quality of life on all-cause mortality in prostate cancer patients: data from CaPSURE (cancer of the prostate strategic urologic research endeavor) database. Qual Life Res. 2009 Oct; 18(8):1019-27.
        View in: PubMed PMC2744792
      149. Porten SP, Cooperberg MR, Carroll PR. The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease. BJU Int. 2010 Feb; 105(4):472-5.
        View in: PubMed PMC2821458
      150. Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR, Akaza H. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol. 2009 Sep 10; 27(26):4306-13.
        View in: PubMed PMC2744272
      151. Cooperberg MR, Carroll PR. Prostate-cancer screening. N Engl J Med. 2009 Jul 9; 361(2):203; author reply 204-5.
        View in: PubMed
      152. Cooperberg MR, Kane CJ, Cowan JE, Carroll PR. Adequacy of lymphadenectomy among men undergoing robot-assisted laparoscopic radical prostatectomy. BJU Int. 2010 Jan; 105(1):88-92.
        View in: PubMed
      153. Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009 Jun 16; 101(12):878-87.
        View in: PubMed PMC2697208
      154. Davies BJ, Smaldone MC, Sadetsky N, Dall'era M, Carroll PR. The impact of obesity on overall and cancer specific survival in men with prostate cancer. J Urol. 2009 Jul; 182(1):112-7; discussion 117.
        View in: PubMed
      155. Dall'Era MA, Carroll PR. Outcomes and follow-up strategies for patients on active surveillance. Curr Opin Urol. 2009 May; 19(3):258-62.
        View in: PubMed
      156. Michalski JM, Roach M, Merrick G, Anscher MS, Beyer DC, Lawton CA, Lee WR, Pollack A, Rosenthal SA, Vijayakumar S, Carroll PR. ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate. Int J Radiat Oncol Biol Phys. 2009 Jul 1; 74(3):667-72.
        View in: PubMed
      157. Eisenberg ML, Cowan JE, Davies BJ, Carroll PR, Shinohara K. The importance of tumor palpability and transrectal ultrasonographic appearance in the contemporary clinical staging of prostate cancer. Urol Oncol. 2011 Mar-Apr; 29(2):171-6.
        View in: PubMed
      158. Eisenberg ML, Davies BJ, Cooperberg MR, Cowan JE, Carroll PR. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol. 2010 Apr; 57(4):622-9.
        View in: PubMed PMC2930030
      159. David KA, Mallin K, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000. Cancer. 2009 Apr 1; 115(7):1435-47.
        View in: PubMed
      160. Ross PL, Cheng I, Liu X, Cicek MS, Carroll PR, Casey G, Witte JS. Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer. BMC Cancer. 2009; 9:69.
        View in: PubMed PMC2657151
      161. Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll PR. Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol. 2009 Apr; 181(4):1628-33; discussion 1633-4.
        View in: PubMed
      162. Dall'era MA, Hosang N, Konety B, Cowan JE, Carroll PR. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease. J Urol. 2009 Apr; 181(4):1622-7; discussion 1627.
        View in: PubMed
      163. Chen RC, Sadetsky N, Chen MH, Carroll PR, D'Amico AV. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy. Int J Radiat Oncol Biol Phys. 2009 Sep 1; 75(1):36-9.
        View in: PubMed
      164. Whitson J, Berry A, Carroll P, Konety B. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int. 2009 Aug; 104(3):336-9.
        View in: PubMed
      165. Konety BR, Cooperberg MR, Carroll PR. Are age-based criteria the best way to determine eligibility for prostate cancer screening? Ann Intern Med. 2009 Feb 3; 150(3):220-1; author reply 221-2.
        View in: PubMed
      166. Breyer BN, Whitson JM, Carroll PR, Konety BR. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol. 2010 Sep-Oct; 28(5):510-4.
        View in: PubMed PMC3565601
      167. Karl A, Carroll PR, Gschwend JE, Knüchel R, Montorsi F, Stief CG, Studer UE. The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol. 2009 Apr; 55(4):826-35.
        View in: PubMed
      168. Odisho AY, Fradet V, Cooperberg MR, Ahmad AE, Carroll PR. Geographic distribution of urologists throughout the United States using a county level approach. J Urol. 2009 Feb; 181(2):760-5; discussion 765-6.
        View in: PubMed
      169. Sartor AO, Hricak H, Wheeler TM, Coleman J, Penson DF, Carroll PR, Rubin MA, Scardino PT. Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology. 2008 Dec; 72(6 Suppl):S12-24.
        View in: PubMed
      170. Zerbib M, Zelefsky MJ, Higano CS, Carroll PR. Conventional treatments of localized prostate cancer. Urology. 2008 Dec; 72(6 Suppl):S25-35.
        View in: PubMed
      171. Marberger M, Carroll PR, Zelefsky MJ, Coleman JA, Hricak H, Scardino PT, Abenhaim LL. New treatments for localized prostate cancer. Urology. 2008 Dec; 72(6 Suppl):S36-43.
        View in: PubMed
      172. Simone NL, Singh AK, Cowan JE, Soule BP, Carroll PR, Litwin MS. Pretreatment predictors of death from other causes in men with prostate cancer. J Urol. 2008 Dec; 180(6):2447-51; discussion 2451-2.
        View in: PubMed PMC3013289
      173. White WM, Sadetsky N, Waters WB, Carroll PR, Litwin MS. Quality of life in men with locally advanced adenocarcinoma of the prostate: an exploratory analysis using data from the CaPSURE database. J Urol. 2008 Dec; 180(6):2409-13; discussion 2414.
        View in: PubMed
      174. Wu AK, Cooperberg MR, Sadetsky N, Carroll PR. Health related quality of life in patients treated with multimodal therapy for prostate cancer. J Urol. 2008 Dec; 180(6):2415-22; discussion 2422.
        View in: PubMed
      175. Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UE. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol. 2009 Jan; 55(1):62-75.
        View in: PubMed PMC3090670
      176. Hong YM, Hu JC, Paciorek AT, Knight SJ, Carroll PR. Impact of radical prostatectomy positive surgical margins on fear of cancer recurrence: results from CaPSURE. Urol Oncol. 2010 May-Jun; 28(3):268-73.
        View in: PubMed
      177. Ornish D, Lin J, Daubenmier J, Weidner G, Epel E, Kemp C, Magbanua MJ, Marlin R, Yglecias L, Carroll PR, Blackburn EH. Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol. 2008 Nov; 9(11):1048-57.
        View in: PubMed
      178. Paris PL, Sridharan S, Hittelman AB, Kobayashi Y, Perner S, Huang G, Simko J, Carroll P, Rubin MA, Collins C. An oncogenic role for the multiple endocrine neoplasia type 1 gene in prostate cancer. Prostate Cancer Prostatic Dis. 2009; 12(2):184-91.
        View in: PubMed PMC2844124
      179. Barocas DA, Cowan JE, Smith JA, Carroll PR. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol. 2008 Oct; 180(4):1330-4; discussion 1334-5.
        View in: PubMed
      180. Frattaroli J, Weidner G, Dnistrian AM, Kemp C, Daubenmier JJ, Marlin RO, Crutchfield L, Yglecias L, Carroll PR, Ornish D. Clinical events in prostate cancer lifestyle trial: results from two years of follow-up. Urology. 2008 Dec; 72(6):1319-23.
        View in: PubMed
      181. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer. 2008 Jul 1; 113(1):78-83.
        View in: PubMed
      182. Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll PR, Zektzer AS, Kurhanewicz J. Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn Reson Med. 2008 Jul; 60(1):33-40.
        View in: PubMed PMC2643975
      183. Ornish D, Magbanua MJ, Weidner G, Weinberg V, Kemp C, Green C, Mattie MD, Marlin R, Simko J, Shinohara K, Haqq CM, Carroll PR. Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci U S A. 2008 Jun 17; 105(24):8369-74.
        View in: PubMed PMC2430265
      184. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008 Jun 15; 112(12):2664-70.
        View in: PubMed
      185. Cooperberg MR, Mallin K, Ritchey J, Villalta JD, Carroll PR, Kane CJ. Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004. J Urol. 2008 Jun; 179(6):2131-5.
        View in: PubMed
      186. Arredondo SA, Downs TM, Lubeck DP, Pasta DJ, Silva SJ, Wallace KL, Carroll PR. Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J Urol. 2008 May; 179(5 Suppl):S14-8.
        View in: PubMed
      187. Cabrera AR, Coakley FV, Westphalen AC, Lu Y, Zhao S, Shinohara K, Carroll PR, Kurhanewicz J. Prostate cancer: is inapparent tumor at endorectal MR and MR spectroscopic imaging a favorable prognostic finding in patients who select active surveillance? Radiology. 2008 May; 247(2):444-50.
        View in: PubMed PMC3705558
      188. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE, Wallace ME, Kantoff PW, Carroll PR. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008 Apr 15; 112(8):1650-9.
        View in: PubMed
      189. Cooperberg MR, Cowan J, Broering JM, Carroll PR. High-risk prostate cancer in the United States, 1990-2007. World J Urol. 2008 Jun; 26(3):211-8.
        View in: PubMed PMC2948572
      190. Walsh TJ, Davies BJ, Croughan MS, Carroll PR, Turek PJ. Racial differences among boys with testicular germ cell tumors in the United States. J Urol. 2008 May; 179(5):1961-5.
        View in: PubMed
      191. Bellizzi KM, Latini DM, Cowan JE, DuChane J, Carroll PR. Fear of recurrence, symptom burden, and health-related quality of life in men with prostate cancer. Urology. 2008 Dec; 72(6):1269-73.
        View in: PubMed
      192. Woldrich JM, Mallin K, Ritchey J, Carroll PR, Kane CJ. Sex differences in renal cell cancer presentation and survival: an analysis of the National Cancer Database, 1993-2004. J Urol. 2008 May; 179(5):1709-13; discussion 1713.
        View in: PubMed
      193. Konety BR, Cowan JE, Carroll PR. Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. J Urol. 2008 May; 179(5):1797-803; discussion 1803.
        View in: PubMed
      194. Sadetsky N, Lubeck DP, Pasta DJ, Latini DM, DuChane J, Carroll PR. Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor. BJU Int. 2008 Mar; 101(6):691-7.
        View in: PubMed
      195. Davies BJ, Walsh TJ, Ross PL, Knight SJ, Sadetsky N, Carroll PR, Kane CJ. Effect of BMI on primary treatment of prostate cancer. Urology. 2008 Aug; 72(2):406-11.
        View in: PubMed
      196. Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol. 2008 Mar; 179(3):906-10; discussion 910.
        View in: PubMed
      197. Lee IH, Sadetsky N, Carroll PR, Sandler HM. The impact of treatment choice for localized prostate cancer on response to phosphodiesterase inhibitors. J Urol. 2008 Mar; 179(3):1072-6; discussion 1076.
        View in: PubMed
      198. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer. 2008 Jan 15; 112(2):307-14.
        View in: PubMed
      199. Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol. 2008 Jan; 18(1):71-7.
        View in: PubMed PMC2804482
      200. Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. Urology. 2008 Jan; 71(1):136-40.
        View in: PubMed
      201. Macdonald OK, D'Amico AV, Sadetsky N, Shrieve DC, Carroll PR. Predicting PSA failure following salvage radiotherapy for a rising PSA post-prostatectomy: from the CaPSURE database. Urol Oncol. 2008 May-Jun; 26(3):271-5.
        View in: PubMed
      202. Scales CD, Moul JW, Curtis LH, Elkin EP, Hughes ME, Carroll PR. Prostate cancer in the Baby Boomer generation: results from CaPSURE. Urology. 2007 Dec; 70(6):1162-7.
        View in: PubMed
      203. Westphalen AC, Coakley FV, Qayyum A, Swanson M, Simko JP, Lu Y, Zhao S, Carroll PR, Yeh BM, Kurhanewicz J. Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging. Radiology. 2008 Jan; 246(1):177-84.
        View in: PubMed
      204. Shah JB, McKiernan JM, Elkin EP, Carroll PR, Meng MV. Prostate biopsy patterns in the CaPSURE database: evolution with time and impact on outcome after prostatectomy. J Urol. 2008 Jan; 179(1):136-40.
        View in: PubMed
      205. Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, Wheeler TM, Fine SW, Trachtenberg J, Rubin MA, Ohori M, Kuroiwa K, Rossignol M, Abenhaim L. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007 Dec; 178(6):2260-7.
        View in: PubMed
      206. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007 Oct 17; 99(20):1516-24.
        View in: PubMed
      207. Sadetsky N, Elkin EP, Latini DM, DuChane J, Carroll PR. Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database. Prostate Cancer Prostatic Dis. 2008; 11(3):280-7.
        View in: PubMed
      208. Walsh TJ, Dall'Era MA, Croughan MS, Carroll PR, Turek PJ. Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer. J Urol. 2007 Oct; 178(4 Pt 1):1440-6; discussion 1446.
        View in: PubMed
      209. Alexander BM, Chen MH, Carroll P, D'Amico AV. Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response. Urology. 2007 Aug; 70(2):320-3.
        View in: PubMed
      210. Kawachi MH, Bahnson RR, Barry M, Carroll PR, Carter HB, Catalona WJ, Epstein JI, Etzioni RB, Hemstreet GP, Howe RJ, Kopin JD, Lange PH, Lilja H, Mohler J, Moul J, Nadler RB, Patterson S, Pollack A, Presti JC, Stroup AM, Urban DA, Wake R, Wei JT. Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Aug; 5(7):714-36.
        View in: PubMed
      211. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007 Sep; 178(3 Pt 2):S14-9.
        View in: PubMed PMC2987559
      212. Kantoff PW, Beer TM, D'Amico AV, Dipaola RS, Eisenberger MA, Hussain MH, Kelly WK, Mathew P, Morris MJ, Ryan CJ, Sandler HM, Thompson IM, Carroll PR. Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference. J Urol. 2007 Sep; 178(3 Pt 2):S5-8; quiz S4.
        View in: PubMed
      213. Hart SL, Latini DM, Cowan JE, Carroll PR. Fear of recurrence, treatment satisfaction, and quality of life after radical prostatectomy for prostate cancer. Support Care Cancer. 2008 Feb; 16(2):161-9.
        View in: PubMed
      214. Latini DM, Hart SL, Knight SJ, Cowan JE, Ross PL, Duchane J, Carroll PR. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol. 2007 Sep; 178(3 Pt 1):826-31; discussion 831-2.
        View in: PubMed
      215. Macdonald OK, D'Amico AV, Sadetsky N, Shrieve DC, Carroll PR. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database. Urology. 2007 Jul; 70(1):106-10.
        View in: PubMed
      216. Ryan CJ, Elkin EP, Cowan J, Carroll PR. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE. Cancer. 2007 Jul 1; 110(1):81-6.
        View in: PubMed
      217. Elliott SP, Meng MV, Elkin EP, McAninch JW, Duchane J, Carroll PR. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. J Urol. 2007 Aug; 178(2):529-34; discussion 534.
        View in: PubMed
      218. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol. 2007 Aug; 178(2):451-4.
        View in: PubMed
      219. Wright JL, Lin DW, Cowan JE, Carroll PR, Litwin MS. Quality of life in young men after radical prostatectomy. Prostate Cancer Prostatic Dis. 2008; 11(1):67-73.
        View in: PubMed
      220. Dall'Era M, Carroll PR. Prostate cancer--more information and more questions. J Urol. 2007 May; 177(5):1607-8.
        View in: PubMed
      221. Knight SJ, Latini DM, Hart SL, Sadetsky N, Kane CJ, DuChane J, Carroll PR. Education predicts quality of life among men with prostate cancer cared for in the Department of Veterans Affairs: a longitudinal quality of life analysis from CaPSURE. Cancer. 2007 May 1; 109(9):1769-76.
        View in: PubMed
      222. Konety BR, Sadetsky N, Carroll PR. Recovery of urinary continence following radical prostatectomy: the impact of prostate volume--analysis of data from the CaPSURE Database. J Urol. 2007 Apr; 177(4):1423-5; discussion 1425-6.
        View in: PubMed
      223. D'Amico AV, McLeod DG, Carroll PR, Cullen J, Chen MH. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality. Cancer. 2007 Apr 1; 109(7):1290-5.
        View in: PubMed
      224. Lee WR, Sharkey J, Cowan JE, DuChane J, Carroll PR. Prostate brachytherapy: a descriptive analysis from CaPSURE. Brachytherapy. 2007 Apr-Jun; 6(2):123-8.
        View in: PubMed
      225. Boorjian S, Cowan JE, Konety BR, DuChane J, Tewari A, Carroll PR, Kane CJ. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol. 2007 Mar; 177(3):883-7; discussion 887-8.
        View in: PubMed
      226. Wilson LS, Tesoro R, Elkin EP, Sadetsky N, Broering JM, Latini DM, DuChane J, Mody RR, Carroll PR. Cumulative cost pattern comparison of prostate cancer treatments. Cancer. 2007 Feb 1; 109(3):518-27.
        View in: PubMed
      227. Konety BR, Allareddy V, Carroll PR. Factors affecting outcomes after radical cystectomy in African Americans. Cancer. 2007 Feb 1; 109(3):542-8.
        View in: PubMed
      228. Berglund RK, Sadetsky N, DuChane J, Carroll PR, Klein EA. Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE. J Urol. 2007 Feb; 177(2):526-29; discussion 529-30.
        View in: PubMed
      229. Dewell A, Weidner G, Sumner MD, Barnard RJ, Marlin RO, Daubenmier JJ, Chi C, Carroll PR, Ornish D. Relationship of dietary protein and soy isoflavones to serum IGF-1 and IGF binding proteins in the Prostate Cancer Lifestyle Trial. Nutr Cancer. 2007; 58(1):35-42.
        View in: PubMed
      230. Arredondo SA, Latini DM, Sadetsky N, Kawakami J, Pasta DJ, DuChane J, Carroll PR. Quality of life for men receiving a second treatment for prostate cancer. J Urol. 2007 Jan; 177(1):273-8; discussion 278-9.
        View in: PubMed
      231. Coakley FV, Chen I, Qayyum A, Westphalen AC, Carroll PR, Hricak H, Chen MH, Kurhanewicz J. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging. BJU Int. 2007 Jan; 99(1):41-5.
        View in: PubMed
      232. Hom JJ, Coakley FV, Simko JP, Lu Y, Qayyum A, Westphalen AC, Schmitt LD, Carroll PR, Kurhanewicz J. High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features--initial experience. Radiology. 2007 Feb; 242(2):483-9.
        View in: PubMed
      233. Latini DM, Chan JM, Cowan JE, Arredondo SA, Kane CJ, Penson DF, DuChane J, Carroll PR. Health-related quality of life for men with prostate cancer and diabetes: a longitudinal analysis from CaPSURE. Urology. 2006 Dec; 68(6):1242-7.
        View in: PubMed
      234. Paris PL, Hofer MD, Albo G, Kuefer R, Gschwend JE, Hautmann RE, Fridyland J, Simko J, Carroll PR, Rubin MA, Collins C. Genomic profiling of hormone-naïve lymph node metastases in patients with prostate cancer. Neoplasia. 2006 Dec; 8(12):1083-9.
        View in: PubMed PMC1783716
      235. Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer. 2006 Dec 1; 107(11):2597-603.
        View in: PubMed
      236. Thompson IM, Carroll PR, Carducci MA. Recommendations for defining and treating high risk localized prostate cancer. J Urol. 2006 Dec; 176(6 Pt 2):S6-S10; quiz S3-5.
        View in: PubMed
      237. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC, Amling CL, Terris MK, Aronson WJ, Kane CJ, Carroll PR. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer. 2006 Nov 15; 107(10):2384-91.
        View in: PubMed
      238. Kawakami J, Meng MV, Sadetsky N, Latini DM, Duchane J, Carroll PR. Changing patterns of pelvic lymphadenectomy for prostate cancer: results from CaPSURE. J Urol. 2006 Oct; 176(4 Pt 1):1382-6.
        View in: PubMed
      239. Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol. 2006 Sep-Oct; 24(5):396-402.
        View in: PubMed
      240. Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology. 2006 Aug; 68(2):342-7.
        View in: PubMed
      241. Eisenberg MS, Meng MV, Master VA, Stoller ML, Rini BI, Carroll PR, Kane CJ. Laparoscopic versus open cytoreductive nephrectomy in advanced renal-cell carcinoma. J Endourol. 2006 Jul; 20(7):504-8.
        View in: PubMed
      242. Meng MV, Elkin EP, DuChane J, Carroll PR. Impact of increased number of biopsies on the nature of prostate cancer identified. J Urol. 2006 Jul; 176(1):63-8; discussion 69.
        View in: PubMed
      243. Swanson MG, Zektzer AS, Tabatabai ZL, Simko J, Jarso S, Keshari KR, Schmitt L, Carroll PR, Shinohara K, Vigneron DB, Kurhanewicz J. Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med. 2006 Jun; 55(6):1257-64.
        View in: PubMed
      244. Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer. 2006 Apr 15; 106(8):1708-14.
        View in: PubMed
      245. Marr PL, Elkin EP, Arredondo SA, Broering JM, DuChane J, Carroll PR. Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE. J Urol. 2006 Apr; 175(4):1326-31.
        View in: PubMed
      246. Carroll PR. Modifying urology residency training: time to speed up or slow down? J Urol. 2006 Mar; 175(3 Pt 1):811-2.
        View in: PubMed
      247. Arredondo SA, Elkin EP, Marr PL, Latini DM, DuChane J, Litwin MS, Carroll PR. Impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: data from CaPSURE. Urology. 2006 Mar; 67(3):559-65.
        View in: PubMed
      248. Latini DM, Elkin EP, Cooperberg MR, Sadetsky N, Duchane J, Carroll PR. Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE. Cancer. 2006 Feb 15; 106(4):789-95.
        View in: PubMed
      249. Penfold J, Staples E, Tucker I, Carroll P, Clayton I, Cowan JS, Lawton G, Amin S, Ferrante A, Ruddock N. Elongational flow induced ordering in surfactant micelles and mesophases. J Phys Chem B. 2006 Jan 19; 110(2):1073-82.
        View in: PubMed
      250. Carroll PR, Coakley FV, Kurhanewicz J. Magnetic resonance imaging and spectroscopy of prostate cancer. Rev Urol. 2006; 8 Suppl 1:S4-S10.
        View in: PubMed PMC1578527
      251. Enokida H, Shiina H, Urakami S, Terashima M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Igawa M, Dahiya R. Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma. Cancer. 2006 Jan 1; 106(1):79-86.
        View in: PubMed
      252. Hom JJ, Coakley FV, Simko JP, Qayyum A, Lu Y, Schmitt L, Carroll PR, Kurhanewicz J. Prostate cancer: endorectal MR imaging and MR spectroscopic imaging--distinction of true-positive results from chance-detected lesions. Radiology. 2006 Jan; 238(1):192-9.
        View in: PubMed
      253. Greene KL, Elkin EP, Karapetian A, Duchane J, Carroll PR, Kane CJ. Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: results from CaPSURE. J Urol. 2006 Jan; 175(1):125-9; discussion 129.
        View in: PubMed
      254. Daubenmier JJ, Weidner G, Marlin R, Crutchfield L, Dunn-Emke S, Chi C, Gao B, Carroll P, Ornish D. Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance. Urology. 2006 Jan; 67(1):125-30.
        View in: PubMed
      255. Chan JM, Elkin EP, Silva SJ, Broering JM, Latini DM, Carroll PR. Total and specific complementary and alternative medicine use in a large cohort of men with prostate cancer. Urology. 2005 Dec; 66(6):1223-8.
        View in: PubMed
      256. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005 Nov 10; 23(32):8146-51.
        View in: PubMed
      257. Bassett WW, Cooperberg MR, Sadetsky N, Silva S, DuChane J, Pasta DJ, Chan JM, Anast JW, Carroll PR, Kane CJ. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology. 2005 Nov; 66(5):1060-5.
        View in: PubMed
      258. Greene KL, Cowan JE, Cooperberg MR, Meng MV, DuChane J, Carroll PR. Who is the average patient presenting with prostate cancer? Urology. 2005 Nov; 66(5 Suppl):76-82.
        View in: PubMed
      259. Master VA, Chi T, Simko JP, Weinberg V, Carroll PR. The independent impact of extended pattern biopsy on prostate cancer stage migration. J Urol. 2005 Nov; 174(5):1789-93; discussion 1793.
        View in: PubMed
      260. Park S, Meng MV, Elkin EP, Speight JL, DuChane J, Carroll PR. Androgen deprivation use with external beam radiation for prostate cancer: results from CaPSURE. J Urol. 2005 Nov; 174(5):1802-7.
        View in: PubMed
      261. Ogishima T, Shiina H, Breault JE, Terashima M, Honda S, Enokida H, Urakami S, Tokizane T, Kawakami T, Ribeiro-Filho LA, Fujime M, Kane CJ, Carroll PR, Igawa M, Dahiya R. Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer. Oncogene. 2005 Oct 13; 24(45):6765-72.
        View in: PubMed
      262. Haqq C, Li R, Khodabakhsh D, Frolov A, Ginzinger D, Thompson T, Wheeler T, Carroll P, Ayala G. Ethnic and racial differences in prostate stromal estrogen receptor alpha. Prostate. 2005 Oct 1; 65(2):101-9.
        View in: PubMed
      263. Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, Pejavar S, Mehta K, Carroll P, Simko JP, Waldman FM. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res. 2005 Oct 1; 11(19 Pt 1):7012-22.
        View in: PubMed
      264. Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005 Oct 1; 23(28):6992-8.
        View in: PubMed
      265. Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW, D'Amico AV. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol. 2005 Sep 20; 23(27):6556-60.
        View in: PubMed
      266. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6582-8.
        View in: PubMed
      267. Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ, Dunn-Emke S, Crutchfield L, Jacobs FN, Barnard RJ, Aronson WJ, McCormac P, McKnight DJ, Fein JD, Dnistrian AM, Weinstein J, Ngo TH, Mendell NR, Carroll PR. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol. 2005 Sep; 174(3):1065-9; discussion 1069-70.
        View in: PubMed
      268. Chan JM, Latini DM, Cowan J, Duchane J, Carroll PR. History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States). Cancer Causes Control. 2005 Sep; 16(7):789-97.
        View in: PubMed
      269. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Pookot D, Li LC, Tabatabai ZL, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. Int J Cancer. 2005 Aug 20; 116(2):174-81.
        View in: PubMed
      270. Master VA, Gottschalk AR, Kane C, Carroll PR. Management of isolated renal fossa recurrence following radical nephrectomy. J Urol. 2005 Aug; 174(2):473-7; discussion 477.
        View in: PubMed
      271. Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol. 2005 Jul; 174(1):14-20.
        View in: PubMed
      272. Langenstroer P, Carroll P, Thrasher JB. Clinical and pathological characteristics of unstageable prostate cancer: analysis of the CaPSURE database. J Urol. 2005 Jul; 174(1):118-20.
        View in: PubMed
      273. Zhao H, Shiina H, Greene KL, Li LC, Tanaka Y, Kishi H, Igawa M, Kane CJ, Carroll P, Dahiya R. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer. Cancer. 2005 Jul 1; 104(1):44-52.
        View in: PubMed
      274. Paris PL, Weinberg V, Simko J, Andaya A, Albo G, Rubin MA, Carroll PR, Collins C. Preliminary evaluation of prostate cancer metastatic risk biomarkers. Int J Biol Markers. 2005 Jul-Sep; 20(3):141-5.
        View in: PubMed
      275. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Carroll P, Waldman FM. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res. 2005 Jun 1; 11(11):4044-55.
        View in: PubMed
      276. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005 Jun; 173(6):1938-42.
        View in: PubMed PMC2948569
      277. Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol. 2005 May; 173(5):1557-61.
        View in: PubMed
      278. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. J Urol. 2005 May; 173(5):1572-6.
        View in: PubMed
      279. Carducci MA, Carroll PR. Multidisciplinary management of advanced prostate cancer: changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials. Urology. 2005 May; 65(5 Suppl):18-22; discussion 22.
        View in: PubMed
      280. Anast JW, Sadetsky N, Pasta DJ, Bassett WW, Latini D, DuChane J, Chan JM, Cooperberg MR, Carroll PR, Kane CJ. The impact of obesity on health related quality of life before and after radical prostatectomy (data from CaPSURE). J Urol. 2005 Apr; 173(4):1132-8.
        View in: PubMed
      281. Carroll PR. Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both? J Urol. 2005 Apr; 173(4):1061-2.
        View in: PubMed
      282. Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ, Carroll PR. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol. 2005 Apr; 173(4):1126-31.
        View in: PubMed
      283. Retz MM, Sidhu SS, Blaveri E, Kerr SC, Dolganov GM, Lehmann J, Carroll P, Simko J, Waldman FM, Basbaum C. CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells. Int J Cancer. 2005 Mar 20; 114(2):182-9.
        View in: PubMed
      284. Shiina H, Breault JE, Basset WW, Enokida H, Urakami S, Li LC, Okino ST, Deguchi M, Kaneuchi M, Terashima M, Yoneda T, Shigeno K, Carroll PR, Igawa M, Dahiya R. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer. Cancer Res. 2005 Mar 15; 65(6):2130-8.
        View in: PubMed
      285. Sheriff SK, Shohara RA, Dumican SB, Small EJ, Carroll PR, Chan JM. Lifestyle correlates of health perception and treatment satisfaction in a clinical cohort of men with prostate cancer. Clin Prostate Cancer. 2005 Mar; 3(4):239-45.
        View in: PubMed
      286. Kane CJ, Bassett WW, Sadetsky N, Silva S, Wallace K, Pasta DJ, Cooperberg MR, Chan JM, Carroll PR. Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. J Urol. 2005 Mar; 173(3):732-6.
        View in: PubMed
      287. Sadetsky N, Lubeck DP, Latini DM, Pasta DJ, Kawakami J, DuChane J, Carroll PR. Demographics, insurance coverage, and utilization of medical services in newly diagnosed prostate cancer: data from caPSURE. Manag Care Interface. 2005 Feb; 18(2):25-30.
        View in: PubMed
      288. Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst. 2005 Jan 19; 97(2):103-15.
        View in: PubMed
      289. Breault JE, Shiina H, Igawa M, Ribeiro-Filho LA, Deguchi M, Enokida H, Urakami S, Terashima M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):557-64.
        View in: PubMed
      290. Kawakami T, Shiina H, Igawa M, Deguchi M, Nakajima K, Ogishima T, Tokizane T, Urakami S, Enokida H, Miura K, Ishii N, Kane CJ, Carroll PR, Dahiya R. Inactivation of the hMSH3 mismatch repair gene in bladder cancer. Biochem Biophys Res Commun. 2004 Dec 17; 325(3):934-42.
        View in: PubMed
      291. Zhao H, Li LC, Okino ST, Kane CJ, Carroll PR, Dahiya R. Kidney gene database: a curated and integrated database of genes involved in kidney disease. J Urol. 2004 Dec; 172(6 Pt 1):2344-6.
        View in: PubMed
      292. Jung JA, Coakley FV, Vigneron DB, Swanson MG, Qayyum A, Weinberg V, Jones KD, Carroll PR, Kurhanewicz J. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology. 2004 Dec; 233(3):701-8.
        View in: PubMed
      293. Master VA, Shinohara K, Carroll PR. Ferromagnetic thermal ablation of locally recurrent prostate cancer: prostate specific antigen results and immediate/intermediate morbidities. J Urol. 2004 Dec; 172(6 Pt 1):2197-202.
        View in: PubMed
      294. Speight JL, Elkin EP, Pasta DJ, Silva S, Lubeck DP, Carroll PR, Litwin MS. Longitudinal assessment of changes in sexual function and bother in patients treated with external beam radiotherapy or brachytherapy, with and without neoadjuvant androgen ablation: data from CaPSURE. Int J Radiat Oncol Biol Phys. 2004 Nov 15; 60(4):1066-75.
        View in: PubMed
      295. Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PW. Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. J Urol. 2004 Nov; 172(5 Pt 2):S3-5.
        View in: PubMed
      296. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol. 2004 Nov; 172(5 Pt 2):S42-6; discussion S46-7.
        View in: PubMed
      297. Carroll PR. The impact of patient advocacy: the University of California-San Francisco experience. J Urol. 2004 Nov; 172(5 Pt 2):S58-61; discussion S61-2.
        View in: PubMed
      298. Arredondo SA, Downs TM, Lubeck DP, Pasta DJ, Silva SJ, Wallace KL, Carroll PR. Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J Urol. 2004 Nov; 172(5 Pt 1):1830-4.
        View in: PubMed
      299. Chan JM, Jou RM, Carroll PR. The relative impact and future burden of prostate cancer in the United States. J Urol. 2004 Nov; 172(5 Pt 2):S13-6; discussion S17.
        View in: PubMed
      300. Watson JE, Kamkar S, James K, Kowbel D, Andaya A, Paris PL, Simko J, Carroll P, McAlhany S, Rowley D, Collins C. Molecular analysis of WFDC1/ps20 gene in prostate cancer. Prostate. 2004 Oct 1; 61(2):192-9.
        View in: PubMed
      301. Qayyum A, Coakley FV, Lu Y, Olpin JD, Wu L, Yeh BM, Carroll PR, Kurhanewicz J. Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol. 2004 Oct; 183(4):1079-83.
        View in: PubMed
      302. Enokida H, Shiina H, Igawa M, Ogishima T, Kawakami T, Bassett WW, Anast JW, Li LC, Urakami S, Terashima M, Verma M, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res. 2004 Sep 1; 64(17):5956-62.
        View in: PubMed
      303. Cooperberg MR, Park S, Carroll PR. Prostate cancer 2004: insights from national disease registries. Oncology (Williston Park). 2004 Sep; 18(10):1239-47; discussion 1248-50, 1256-8.
        View in: PubMed
      304. Sasaki M, Nomoto M, Yonezawa S, Nakagawa M, Sakuragi N, Fujimoto S, Carroll PR, Dahiya R. Distribution of a single nucleotide polymorphism on codon 211 of the androgen receptor gene and its correlation with human renal cell cancer in Japanese patients. Biochem Biophys Res Commun. 2004 Aug 20; 321(2):468-71.
        View in: PubMed
      305. Li LC, Shiina H, Deguchi M, Zhao H, Okino ST, Kane CJ, Carroll PR, Igawa M, Dahiya R. Age-dependent methylation of ESR1 gene in prostate cancer. Biochem Biophys Res Commun. 2004 Aug 20; 321(2):455-61.
        View in: PubMed
      306. Cooperberg MR, Broering JM, Latini DM, Litwin MS, Wallace KL, Carroll PR. Patterns of practice in the United States: insights from CaPSURE on prostate cancer management. Curr Urol Rep. 2004 Jun; 5(3):166-72.
        View in: PubMed
      307. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004 Jun 1; 22(11):2141-9.
        View in: PubMed PMC2997214
      308. Greene KL, Meng MV, Elkin EP, Cooperberg MR, Pasta DJ, Kattan MW, Wallace K, Carroll PR. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure). J Urol. 2004 Jun; 171(6 Pt 1):2255-9.
        View in: PubMed
      309. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JE, Volik S, Albertson DG, Pinkel D, Alers JC, van der Kwast TH, Vissers KJ, Schroder FH, Wildhagen MF, Febbo PG, Chinnaiyan AM, Pienta KJ, Carroll PR, Rubin MA, Collins C, van Dekken H. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet. 2004 Jul 1; 13(13):1303-13.
        View in: PubMed
      310. Moyad MA, Carroll PR. Lifestyle recommendations to prevent prostate cancer, part I: time to redirect our attention? Urol Clin North Am. 2004 May; 31(2):289-300.
        View in: PubMed
      311. Moyad MA, Carroll PR. Lifestyle recommendations to prevent prostate cancer, part II: time to redirect our attention? Urol Clin North Am. 2004 May; 31(2):301-11.
        View in: PubMed
      312. D'Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst. 2004 Apr 7; 96(7):509-15.
        View in: PubMed
      313. Strohmeyer DM, Berger AP, Moore DH, Bartsch G, Klocker H, Carroll PR, Loening SA, Jensen RH. Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis: association with progression and angiogenesis. Prostate. 2004 Apr 1; 59(1):43-58.
        View in: PubMed
      314. Cooperberg MR, Downs TM, Carroll PR. Radical retropubic prostatectomy frustrated by prior laparoscopic mesh herniorrhaphy. Surgery. 2004 Apr; 135(4):452-3; discussion 454.
        View in: PubMed
      315. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004 Apr; 171(4):1393-401.
        View in: PubMed
      316. Yun EJ, Meng MV, Carroll PR. Evaluation of the patient with hematuria. Med Clin North Am. 2004 Mar; 88(2):329-43.
        View in: PubMed
      317. Master VA, Meng MV, Grossfeld GD, Koppie TM, Hirose R, Carroll PR. Treatment and outcome of invasive bladder cancer in patients after renal transplantation. J Urol. 2004 Mar; 171(3):1085-8.
        View in: PubMed
      318. Hu JC, Elkin EP, Pasta DJ, Lubeck DP, Kattan MW, Carroll PR, Litwin MS. Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol. 2004 Feb; 171(2 Pt 1):703-7; discussion 707-8.
        View in: PubMed
      319. Kane CJ, Mitchell JA, Meng MV, Anast J, Carroll PR, Stoller ML. Laparoscopic partial nephrectomy with temporary arterial occlusion: description of technique and renal functional outcomes. Urology. 2004 Feb; 63(2):241-6.
        View in: PubMed
      320. Mehta SS, Lubeck DP, Sadetsky N, Pasta DJ, Carroll PR. Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE. J Urol. 2004 Jan; 171(1):215-9.
        View in: PubMed
      321. Dhingsa R, Qayyum A, Coakley FV, Lu Y, Jones KD, Swanson MG, Carroll PR, Hricak H, Kurhanewicz J. Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiology. 2004 Jan; 230(1):215-20.
        View in: PubMed
      322. Sasaki M, Kaneuchi M, Sakuragi N, Fujimoto S, Carroll PR, Dahiya R. The polyglycine and polyglutamine repeats in the androgen receptor gene in Japanese and Caucasian populations. Biochem Biophys Res Commun. 2003 Dec 26; 312(4):1244-7.
        View in: PubMed
      323. Cooperberg MR, Small EJ, D'Amico A, Carroll PR. The evolving role of androgen deprivation therapy in the management of prostate cancer. Minerva Urol Nefrol. 2003 Dec; 55(4):219-38.
        View in: PubMed
      324. Meng MV, Elkin EP, Harlan SR, Mehta SS, Lubeck DP, Carroll PR. Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE. J Urol. 2003 Dec; 170(6 Pt 1):2279-83.
        View in: PubMed
      325. Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M, Sellers WR, Smith MR, McMann MC, Kantoff PW. Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. J Urol. 2003 Dec; 170(6 Pt 2):S3-5.
        View in: PubMed
      326. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003 Dec; 170(6 Pt 2):S21-5; discussion S26-7.
        View in: PubMed
      327. Kane CJ, Lubeck DP, Knight SJ, Spitalny M, Downs TM, Grossfeld GD, Pasta DJ, Mehta SS, Carroll PR. Impact of patient educational level on treatment for patients with prostate cancer: data from CaPSURE. Urology. 2003 Dec; 62(6):1035-9.
        View in: PubMed
      328. Downs TM, Sadetsky N, Pasta DJ, Grossfeld GD, Kane CJ, Mehta SS, Carroll PR, Lubeck DP. Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer--data from CaPSURE. J Urol. 2003 Nov; 170(5):1822-7.
        View in: PubMed
      329. Harlan SR, Cooperberg MR, Elkin E, Lubeck DP, Meng M, Mehta SS, Carroll PR. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol. 2003 Nov; 170(5):1804-7.
        View in: PubMed
      330. Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, James JK, Hurd RE, Kurhanewicz J. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med. 2003 Nov; 50(5):944-54.
        View in: PubMed
      331. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003 Sep 17; 95(18):1376-83.
        View in: PubMed
      332. Staack A, Donjacour AA, Brody J, Cunha GR, Carroll P. Mouse urogenital development: a practical approach. Differentiation. 2003 Sep; 71(7):402-13.
        View in: PubMed
      333. Cooperberg M, Lubeck DP, Penson D, Mehta SS, Carroll PR, Kane CJ. Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. J Urol. 2003 Sep; 170(3):905-8.
        View in: PubMed
      334. Cooperberg MR, Master VA, Carroll PR. Health related quality of life significance of single pad urinary incontinence following radical prostatectomy. J Urol. 2003 Aug; 170(2 Pt 1):512-5.
        View in: PubMed
      335. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003 Jul 2; 95(13):981-9.
        View in: PubMed PMC2994265
      336. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003 Jun 1; 21(11):2163-72.
        View in: PubMed
      337. Veltman JA, Fridlyand J, Pejavar S, Olshen AB, Korkola JE, DeVries S, Carroll P, Kuo WL, Pinkel D, Albertson D, Cordon-Cardo C, Jain AN, Waldman FM. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res. 2003 Jun 1; 63(11):2872-80.
        View in: PubMed
      338. Purohit RS, Shinohara K, Meng MV, Carroll PR. Imaging clinically localized prostate cancer. Urol Clin North Am. 2003 May; 30(2):279-93.
        View in: PubMed
      339. Patra SK, Patra A, Zhao H, Carroll P, Dahiya R. Methyl-CpG-DNA binding proteins in human prostate cancer: expression of CXXC sequence containing MBD1 and repression of MBD2 and MeCP2. Biochem Biophys Res Commun. 2003 Mar 21; 302(4):759-66.
        View in: PubMed
      340. Paris PL, Albertson DG, Alers JC, Andaya A, Carroll P, Fridlyand J, Jain AN, Kamkar S, Kowbel D, Krijtenburg PJ, Pinkel D, Schröder FH, Vissers KJ, Watson VJ, Wildhagen MF, Collins C, Van Dekken H. High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays. Am J Pathol. 2003 Mar; 162(3):763-70.
        View in: PubMed PMC1868117
      341. Staack A, Kassis AP, Olshen A, Wang Y, Wu D, Carroll PR, Grossfeld GD, Cunha GR, Hayward SW. Quantitation of apoptotic activity following castration in human prostatic tissue in vivo. Prostate. 2003 Feb 15; 54(3):212-9.
        View in: PubMed
      342. Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol. 2003 Jan; 169(1):157-63.
        View in: PubMed
      343. Cooperberg MR, Koppie TM, Lubeck DP, Ye J, Grossfeld GD, Mehta SS, Carroll PR. How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: data from CaPSURE. Urology. 2003 Jan; 61(1):190-6.
        View in: PubMed
      344. Litwin MS, Saigal CS, Lubeck DP, Li YP, Henning JM, Carroll PR. Health-related quality of life in men with metastatic prostate cancer: the misleading effect of lead-time bias. BJU Int. 2003 Jan; 91(1):9-13.
        View in: PubMed
      345. Grossfeld GD, Latini DM, Downs T, Lubeck DP, Mehta SS, Carroll PR. Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy? J Urol. 2002 Dec; 168(6):2510-5.
        View in: PubMed
      346. Powell IJ, Tangen CM, Miller GJ, Lowe BA, Haas G, Carroll PR, Osswald MB, DeVERE WHITE R, Thompson IM, Crawford ED. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109. J Urol. 2002 Nov; 168(5):2016-9.
        View in: PubMed
      347. Katz D, Koppie TM, Wu D, Meng MV, Grossfeld GD, Sadesky N, Lubeck DP, Carroll PR. Sociodemographic characteristics and health related quality of life in men attending prostate cancer support groups. J Urol. 2002 Nov; 168(5):2092-6.
        View in: PubMed
      348. Grossfeld GD, Li YP, P Lubeck DP, Carroll PR. Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy. Urology. 2002 Sep; 60(3 Suppl 1):57-62; discussion 62-3.
        View in: PubMed
      349. Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):1-6.
        View in: PubMed
      350. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):7-11; discussion 11-2.
        View in: PubMed
      351. Lubeck DP, Grossfeld GD, Carroll PR. A review of measurement of patient preferences for treatment outcomes after prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):72-7; discussion 77-8.
        View in: PubMed
      352. Cooperberg MR, Lubeck DP, Grossfeld GD, Mehta SS, Carroll PR. Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor. J Urol. 2002 Aug; 168(2):491-5.
        View in: PubMed
      353. Grossfeld GD, Li YP, Lubeck DP, Broering JM, Mehta SS, Carroll PR. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. J Urol. 2002 Aug; 168(2):530-5.
        View in: PubMed
      354. Meng MV, Grossfeld GD, Carroll PR, Small EJ. Neoadjuvant strategies for prostate cancer prior to radical prostatectomy. Semin Urol Oncol. 2002 Aug; 20(3 Suppl 1):10-8.
        View in: PubMed
      355. Ribeiro-Filho LA, Franks J, Sasaki M, Shiina H, Li LC, Nojima D, Arap S, Carroll P, Enokida H, Nakagawa M, Yonezawa S, Dahiya R. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Mol Carcinog. 2002 Aug; 34(4):187-98.
        View in: PubMed
      356. Elliott SP, Shinohara K, Logan SL, Carroll PR. Sextant prostate biopsies predict side and sextant site of extracapsular extension of prostate cancer. J Urol. 2002 Jul; 168(1):105-9.
        View in: PubMed
      357. Litwin MS, Lubeck DP, Spitalny GM, Henning JM, Carroll PR. Mental health in men treated for early stage prostate carcinoma: a posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer. 2002 Jul 1; 95(1):54-60.
        View in: PubMed
      358. Master VA, Meng MV, Koppie TM, Carroll PR, Grossfeld GD. Origin of urothelial carcinoma after renal transplant determined by fluorescence in situ hybridization. J Urol. 2002 Jun; 167(6):2521-2.
        View in: PubMed
      359. Goharderakhshan RZ, Sudilovsky D, Carroll LA, Grossfeld GD, Marn R, Carroll PR. Utility of intraoperative frozen section analysis of surgical margins in region of neurovascular bundles at radical prostatectomy. Urology. 2002 May; 59(5):709-14.
        View in: PubMed
      360. Penson DF, Grossfeld GD, Li YP, Henning JM, Lubeck DP, Carroll PR. How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. J Urol. 2002 Apr; 167(4):1653-7; discussion 1657-8.
        View in: PubMed
      361. Coakley FV, Kurhanewicz J, Lu Y, Jones KD, Swanson MG, Chang SD, Carroll PR, Hricak H. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology. 2002 Apr; 223(1):91-7.
        View in: PubMed
      362. Grossfeld GD, Latini DM, Lubeck DP, Broering JM, Li YP, Mehta SS, Carroll PR. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE. Urology. 2002 Apr; 59(4):560-5.
        View in: PubMed
      363. Downs TM, Kane CJ, Grossfeld GD, Meng MV, Carroll PR. Surgery for prostate cancer: rationale, technique and outcomes. Cancer Metastasis Rev. 2002; 21(1):29-44.
        View in: PubMed
      364. Grossfeld GD, Carroll PR, Lindeman N, Meng M, Groshen S, Feng AC, Hawes D, Cote RJ. Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression. Urology. 2002 Jan; 59(1):97-102.
        View in: PubMed
      365. Lubeck DP, Kim H, Grossfeld G, Ray P, Penson DF, Flanders SC, Carroll PR. Health related quality of life differences between black and white men with prostate cancer: data from the cancer of the prostate strategic urologic research endeavor. J Urol. 2001 Dec; 166(6):2281-5.
        View in: PubMed
      366. Mueller-Lisse UG, Vigneron DB, Hricak H, Swanson MG, Carroll PR, Bessette A, Scheidler J, Srivastava A, Males RG, Cha I, Kurhanewicz J. Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. Radiology. 2001 Nov; 221(2):380-90.
        View in: PubMed
      367. Roach M, Kurhanewicz J, Carroll P. Spectroscopy in prostate cancer: hope or hype? Oncology (Williston Park). 2001 Nov; 15(11):1399-410; discussion 1415-6, 1418.
        View in: PubMed
      368. Moul JW, Connelly RR, Lubeck DP, Bauer JJ, Sun L, Flanders SC, Grossfeld GD, Carroll PR. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol. 2001 Oct; 166(4):1322-7.
        View in: PubMed
      369. Grossfeld GD, Carroll PR. Orthotopic urinary diversion with the ileal neobladder. Tech Urol. 2001 Sep; 7(3):196-202.
        View in: PubMed
      370. Grady B, Goharderakhshan R, Chang J, Ribeiro-Filho LA, Perinchery G, Franks J, Presti J, Carroll P, Dahiya R. Frequently deleted loci on chromosome 9 may harbor several tumor suppressor genes in human renal cell carcinoma. J Urol. 2001 Sep; 166(3):1088-92.
        View in: PubMed
      371. Meng MV, Grossfeld GD, Williams GH, Dilworth S, Stoeber K, Mulley TW, Weinberg V, Carroll PR, Tlsty TD. Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Clin Cancer Res. 2001 Sep; 7(9):2712-8.
        View in: PubMed
      372. Li LC, Zhao H, Nakajima K, Oh BR, Ribeiro Filho LA, Carroll P, Dahiya R. Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer. J Urol. 2001 Aug; 166(2):705-9.
        View in: PubMed
      373. Grossfeld GD, Chaudhary UB, Reese DM, Carroll PR, Small EJ. Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology. 2001 Aug; 58(2):240-5.
        View in: PubMed
      374. Grossfeld GD, Small EJ, Lubeck DP, Latini D, Broering JM, Carroll PR. Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. Urology. 2001 Aug; 58(2 Suppl 1):56-64.
        View in: PubMed
      375. Lubeck DP, Grossfeld GD, Carroll PR. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology. 2001 Aug; 58(2 Suppl 1):94-100.
        View in: PubMed
      376. Carroll PR, Fair WR, Grossfeld GD, Heston WD, Lieberman R, Malkowicz SB, Stricker HJ, Sylvester J, Peehl DM, Meyer F, Hart C. Overview consensus statement. Urology. 2001 Aug; 58(2 Suppl 1):1-4.
        View in: PubMed
      377. Koppie TM, Grossfeld GD, Nudell DM, Weinberg VK, Carroll PR. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol. 2001 Jul; 166(1):111-5.
        View in: PubMed
      378. Mueller-Lisse UG, Swanson MG, Vigneron DB, Hricak H, Bessette A, Males RG, Wood PJ, Noworolski S, Nelson SJ, Barken I, Carroll PR, Kurhanewicz J. Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn Reson Med. 2001 Jul; 46(1):49-57.
        View in: PubMed
      379. Meng MV, Carroll PR. Is it necessary to do staging pelvic lymph node dissection for T1c prostate cancer? Curr Urol Rep. 2001 Jun; 2(3):237-41.
        View in: PubMed
      380. Park S, Shinohara K, Grossfeld GD, Carroll PR. Prostate cancer detection in men with prior high grade prostatic intraepithelial neoplasia or atypical prostate biopsy. J Urol. 2001 May; 165(5):1409-14.
        View in: PubMed
      381. Grossfeld GD, Litwin MS, Wolf JS, Hricak H, Shuler CL, Agerter DC, Carroll PR. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up. Urology. 2001 Apr; 57(4):604-10.
        View in: PubMed
      382. Ornish DM, Lee KL, Fair WR, Pettengill EB, Carroll PR. Dietary trial in prostate cancer: Early experience and implications for clinical trial design. Urology. 2001 Apr; 57(4 Suppl 1):200-1.
        View in: PubMed
      383. Carroll PR. Serum prostate-specific antigen for prostate cancer early detection: total, free, age- stratified, or complexed? Urology. 2001 Apr; 57(4):591-3.
        View in: PubMed
      384. Grossfeld GD, Litwin MS, Wolf JS, Hricak H, Shuler CL, Agerter DC, Carroll PR. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology. Urology. 2001 Apr; 57(4):599-603.
        View in: PubMed
      385. Grossfeld GD, Wolf JS, Litwan MS, Hricak H, Shuler CL, Agerter DC, Carroll PR. Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. Am Fam Physician. 2001 Mar 15; 63(6):1145-54.
        View in: PubMed
      386. Penson DF, Schonfeld WH, Flanders SC, Henke CJ, Warolin KL, Carroll PR, Litwin MS. Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CAPSURE database. Urology. 2001 Mar; 57(3):499-503.
        View in: PubMed
      387. Grossfeld GD, Chang JJ, Broering JM, Li YP, Lubeck DP, Flanders SC, Carroll PR. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol. 2001 Mar; 165(3):851-6.
        View in: PubMed
      388. Carroll P, Coley C, McLeod D, Schellhammer P, Sweat G, Wasson J, Zietman A, Thompson I. Prostate-specific antigen best practice policy--part II: prostate cancer staging and post-treatment follow-up. Urology. 2001 Feb; 57(2):225-9.
        View in: PubMed
      389. Carroll P, Coley C, McLeod D, Schellhammer P, Sweat G, Wasson J, Zietman A, Thompson I. Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer. Urology. 2001 Feb; 57(2):217-24.
        View in: PubMed
      390. Grossfeld GD, Carroll PR. Prostate cancer early detection: a clinical perspective. Epidemiol Rev. 2001; 23(1):173-80.
        View in: PubMed
      391. Carroll P. Rising PSA after a radical treatment. Eur Urol. 2001; 40 Suppl 2:9-16.
        View in: PubMed
      392. Goharderakhshan RZ, Grossfeld GD, Kassis A, Shinohara K, Roach M, Carroll PR. Additional treatments and reimbursement rates associated with prostate cancer treatment for patients undergoing radical prostatectomy, interstitial brachytherapy, and external beam radiotherapy. Urology. 2000 Oct 1; 56(4):622-6.
        View in: PubMed
      393. Meng MV, Carroll PR. When is pelvic lymph node dissection necessary before radical prostatectomy? A decision analysis. J Urol. 2000 Oct; 164(4):1235-40.
        View in: PubMed
      394. Muscheck M, Abol-Enein H, Chew K, Moore D, Bhargava V, Ghoneim MA, Carroll PR, Waldman FM. Comparison of genetic changes in schistosome-related transitional and squamous bladder cancers using comparative genomic hybridization. Carcinogenesis. 2000 Sep; 21(9):1721-6.
        View in: PubMed
      395. Grossfeld GD, Chang JJ, Broering JM, Miller DP, Yu J, Flanders SC, Carroll PR. Does the completeness of prostate sampling predict outcome for patients undergoing radical prostatectomy?: data from the CAPSURE database. Urology. 2000 Sep 1; 56(3):430-5.
        View in: PubMed
      396. Wefer AE, Hricak H, Vigneron DB, Coakley FV, Lu Y, Wefer J, Mueller-Lisse U, Carroll PR, Kurhanewicz J. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol. 2000 Aug; 164(2):400-4.
        View in: PubMed
      397. Koppie TM, Grossfeld GD, Miller D, Yu J, Stier D, Broering JM, Lubeck D, Henning JM, Flanders SC, Carroll PR. Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from The CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor. J Urol. 2000 Jul; 164(1):81-8.
        View in: PubMed
      398. Grossfeld GD, Tigrani VS, Nudell D, Roach M, Weinberg VK, Presti JC, Small EJ, Carroll PR. Management of a positive surgical margin after radical prostatectomy: decision analysis. J Urol. 2000 Jul; 164(1):93-9; discussion 100.
        View in: PubMed
      399. Roach M, Chen A, Song J, Diaz A, Presti J, Carroll P. Pretreatment prostate-specific antigen and Gleason score predict the risk of extracapsular extension and the risk of failure following radiotherapy in patients with clinically localized prostate cancer. Semin Urol Oncol. 2000 May; 18(2):108-14.
        View in: PubMed
      400. Oh BR, Sasaki M, Perinchery G, Ryu SB, Park YI, Carroll P, Dahiya R. Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. J Urol. 2000 May; 163(5):1584-7.
        View in: PubMed
      401. Perinchery G, Sasaki M, Angan A, Kumar V, Carroll P, Dahiya R. Deletion of Y-chromosome specific genes in human prostate cancer. J Urol. 2000 Apr; 163(4):1339-42.
        View in: PubMed
      402. Grossfeld GD, Chang JJ, Broering JM, Miller DP, Yu J, Flanders SC, Henning JM, Stier DM, Carroll PR. Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database. J Urol. 2000 Apr; 163(4):1171-7; quiz 1295.
        View in: PubMed
      403. Carroll PR. Prostate biopsy: a wealth of information when done and interpreted correctly. J Clin Oncol. 2000 Mar; 18(6):1161-3.
        View in: PubMed
      404. Li LC, Chui RM, Sasaki M, Nakajima K, Perinchery G, Au HC, Nojima D, Carroll P, Dahiya R. A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res. 2000 Feb 15; 60(4):873-6.
        View in: PubMed
      405. Roach M, Reese D, Weinberg V, Small EJ, Carroll PR. Is the use of anti-androgen monotherapy appropriate in patients with advanced prostate cancer? J Clin Oncol. 2000 Jan; 18(2):448-50.
        View in: PubMed
      406. Tigrani VS, Reese DM, Small EJ, Presti JC, Carroll PR. Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: a retrospective analysis. Urology. 2000 Jan; 55(1):36-40.
        View in: PubMed
      407. Nudell DM, Wefer AE, Hricak H, Carroll PR. Imaging for recurrent prostate cancer. Radiol Clin North Am. 2000 Jan; 38(1):213-29.
        View in: PubMed
      408. Lubeck DP, Litwin MS, Henning JM, Mathias SD, Bloor L, Carroll PR. An instrument to measure patient satisfaction with healthcare in an observational database: results of a validation study using data from CaPSURE. Am J Manag Care. 2000 Jan; 6(1):70-6.
        View in: PubMed
      409. Nudell DM, Grossfeld GD, Weinberg VK, Roach M, Carroll PR. Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology. 1999 Dec; 54(6):1049-57.
        View in: PubMed
      410. Yu KK, Scheidler J, Hricak H, Vigneron DB, Zaloudek CJ, Males RG, Nelson SJ, Carroll PR, Kurhanewicz J. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology. 1999 Nov; 213(2):481-8.
        View in: PubMed
      411. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, Zaloudek CJ, Nelson SJ, Carroll PR, Kurhanewicz J. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. Radiology. 1999 Nov; 213(2):473-80.
        View in: PubMed
      412. Overstreet JW, Fuh VL, Gould J, Howards SS, Lieber MM, Hellstrom W, Shapiro S, Carroll P, Corfman RS, Petrou S, Lewis R, Toth P, Shown T, Roy J, Jarow JP, Bonilla J, Jacobsen CA, Wang DZ, Kaufman KD. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol. 1999 Oct; 162(4):1295-300.
        View in: PubMed
      413. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999 Oct 1; 59(19):5002-11.
        View in: PubMed
      414. Koppie TM, Shinohara K, Grossfeld GD, Presti JC, Carroll PR. The efficacy of cryosurgical ablation of prostate cancer: the University of California, San Francisco experience. J Urol. 1999 Aug; 162(2):427-32.
        View in: PubMed
      415. Morey AF, McAninch JW, Tiller BK, Duckett CP, Carroll PR. Single shot intraoperative excretory urography for the immediate evaluation of renal trauma. J Urol. 1999 Apr; 161(4):1088-92.
        View in: PubMed
      416. Lubeck DP, Litwin MS, Henning JM, Stoddard ML, Flanders SC, Carroll PR. Changes in health-related quality of life in the first year after treatment for prostate cancer: results from CaPSURE. Urology. 1999 Jan; 53(1):180-6.
        View in: PubMed
      417. Grossfeld GD, Muscheck M, Stein JP, Chew K, Cote RJ, Ginsberg DA, Waldman FM, Carroll PR. Cellular proliferation and cell-cell cycle regulatory proteins as prognostic markers for transitional cell carcinoma of the bladder. Adv Exp Med Biol. 1999; 462:425-35.
        View in: PubMed
      418. Kindrick AV, Grossfeld GD, Stier DM, Flanders SC, Henning JM, Carroll PR. Use of imaging tests for staging newly diagnosed prostate cancer: trends from the CaPSURE database. J Urol. 1998 Dec; 160(6 Pt 1):2102-6.
        View in: PubMed
      419. Rogers R, Grossfeld GD, Roach M, Shinohara K, Presti JC, Carroll PR. Radiation therapy for the management of biopsy proved local recurrence after radical prostatectomy. J Urol. 1998 Nov; 160(5):1748-53.
        View in: PubMed
      420. Grossfeld GD, Carroll PR. Evaluation of asymptomatic microscopic hematuria. Urol Clin North Am. 1998 Nov; 25(4):661-76.
        View in: PubMed
      421. Grossfeld GD, Stier DM, Flanders SC, Henning JM, Schonfeld W, Warolin K, Carroll PR. Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database. J Urol. 1998 Oct; 160(4):1398-404.
        View in: PubMed
      422. Yu KK, Hricak H, Grossfeld GD, Carroll PR. Prediction of patient outcome after radical prostatectomy by imaging: choice of outcome measure. Acad Radiol. 1998 Sep; 5 Suppl 2:S347-8.
        View in: PubMed
      423. Hovey RM, Chu L, Balazs M, DeVries S, Moore D, Sauter G, Carroll PR, Waldman FM. Genetic alterations in primary bladder cancers and their metastases. Cancer Res. 1998 Aug 15; 58(16):3555-60.
        View in: PubMed
      424. Turek PJ, Lowther DN, Carroll PR. Fertility issues and their management in men with testis cancer. Urol Clin North Am. 1998 Aug; 25(3):517-31.
        View in: PubMed
      425. Litwin MS, Pasta DJ, Stoddard ML, Henning JM, Carroll PR. Epidemiological trends and financial outcomes in radical prostatectomy among Medicare beneficiaries, 1991 to 1993. J Urol. 1998 Aug; 160(2):445-8.
        View in: PubMed
      426. Mueller P, Carroll P, Bowers E, Moore D, Cher M, Presti J, Wessman M, Pallavicini MG. Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant. Cancer. 1998 Aug 1; 83(3):538-46.
        View in: PubMed
      427. Litwin MS, Lubeck DP, Henning JM, Carroll PR. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol. 1998 Jun; 159(6):1988-92.
        View in: PubMed
      428. Serra AD, Hricak H, Coakley FV, Kim B, Dudley A, Morey A, Tschumper B, Carroll PR. Inconclusive clinical and ultrasound evaluation of the scrotum: impact of magnetic resonance imaging on patient management and cost. Urology. 1998 Jun; 51(6):1018-21.
        View in: PubMed
      429. McCune JM, Loftus R, Schmidt DK, Carroll P, Webster D, Swor-Yim LB, Francis IR, Gross BH, Grant RM. High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest. 1998 Jun 1; 101(11):2301-8.
        View in: PubMed PMC508819
      430. Grossfeld GD, Olumi AF, Connolly JA, Chew K, Gibney J, Bhargava V, Waldman FM, Carroll PR. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol. 1998 May; 159(5):1437-43.
        View in: PubMed
      431. Dahiya R, Deng G, Selph C, Carroll P, Presti J. A novel p53 mutation hotspot at codon 132 (AAG-->AGG) in human renal cancer. Biochem Mol Biol Int. 1998 Feb; 44(2):407-15.
        View in: PubMed
      432. Sarosdy MF, Manyak MJ, Sagalowsky AI, Belldegrun A, Benson MC, Bihrle W, Carroll PR, Ellis WJ, Hudson MA, Sharkey FE. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin. Urology. 1998 Feb; 51(2):226-31.
        View in: PubMed
      433. Grossfeld GD, Small EJ, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology. 1998 Jan; 51(1):137-44.
        View in: PubMed
      434. Aboseif SR, Borirakchanyavat S, Lue TF, Carroll PR. Continence mechanism of the ileal neobladder in women: a urodynamics study. World J Urol. 1998; 16(6):400-4.
        View in: PubMed
      435. Aboseif S, Shinohara K, Borirakchanyavat S, Deirmenjian J, Carroll PR. The effect of cryosurgical ablation of the prostate on erectile function. Br J Urol. 1997 Dec; 80(6):918-22.
        View in: PubMed
      436. Shinohara K, Rhee B, Presti JC, Carroll PR. Cryosurgical ablation of prostate cancer: patterns of cancer recurrence. J Urol. 1997 Dec; 158(6):2206-9; discussion 2209-10.
        View in: PubMed
      437. Connolly JA, Shinohara K, Carroll PR. Cryosurgery for locally advanced (T3) prostate cancer. Semin Urol Oncol. 1997 Nov; 15(4):244-9.
        View in: PubMed
      438. Borirakchanyavat S, Aboseif SR, Carroll PR, Tanagho EA, Lue TF. Continence mechanism of the isolated female urethra: an anatomical study of the intrapelvic somatic nerves. J Urol. 1997 Sep; 158(3 Pt 1):822-6.
        View in: PubMed
      439. Borirakchanyavat S, Bhargava V, Shinohara K, Toke A, Carroll PR, Presti JC. Systematic sextant biopsies in the prediction of extracapsular extension at radical prostatectomy. Urology. 1997 Sep; 50(3):373-8.
        View in: PubMed
      440. Connolly JA, Presti JC, Cher ML, Chew K, Shinohara K, Carroll PR. Accelerated tumor proliferation rates in locally recurrent prostate cancer after radical prostatectomy. J Urol. 1997 Aug; 158(2):515-8.
        View in: PubMed
      441. Dahiya R, McCarville J, Lee C, Hu W, Kaur G, Carroll P, Deng G. Deletion of chromosome 11p15, p12, q22, q23-24 loci in human prostate cancer. Int J Cancer. 1997 Jul 17; 72(2):283-8.
        View in: PubMed
      442. Lubeck DP, Litwin MS, Henning JM, Carroll PR. Measurement of health-related quality of life in men with prostate cancer: the CaPSURE database. Qual Life Res. 1997 Jul; 6(5):385-92.
        View in: PubMed
      443. Balázs M, Carroll P, Kerschmann R, Sauter G, Waldman FM. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization. Genes Chromosomes Cancer. 1997 Jun; 19(2):84-9.
        View in: PubMed
      444. Connolly JA, Shinohara K, Presti JC, Carroll PR. Prostate-specific antigen after cryosurgical ablation of the prostate. Defining the appropriate response. Urol Clin North Am. 1997 May; 24(2):415-20.
        View in: PubMed
      445. Bander NH, Carroll PR, Russo P. Summary of immunohistologic dissection of the human kidney using monoclonal antibodies (by Neil H. Bander, MD, Carlos Cordon-Cardo, MD, PhD, Connie L. Finstad, PhD, Willet F. Whitmore, Jr, MD, E. Darracott Vaughan, Jr, MD, Herbert F. Oettgen, MD, Myron Melamed, MD, and Lloyd J. Old, MD). 1985. Semin Urol Oncol. 1997 May; 15(2):123-9.
        View in: PubMed
      446. Gordon W, Siegmund K, Stanisic TH, McKnight B, Harris IT, Carroll PR, Paradelo JC, Meyers FJ, Chapman RA, Meyskens FL. A study of reproductive function in patients with seminoma treated with radiotherapy and orchidectomy: (SWOG-8711). Southwest Oncology Group. Int J Radiat Oncol Biol Phys. 1997 Apr 1; 38(1):83-94.
        View in: PubMed
      447. Narumi Y, Hricak H, Presti JC, Forstner R, Sica GT, Kuroda C, Sawai Y, Kotake T, Kinouchi T, Carroll PR. MR imaging evaluation of renal cell carcinoma. Abdom Imaging. 1997 Mar-Apr; 22(2):216-25.
        View in: PubMed
      448. Presti JC, Hovey R, Bhargava V, Carroll PR, Shinohara K. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of carcinoma of the prostate: ethnic variations. J Urol. 1997 Mar; 157(3):907-11; discussion 911-2.
        View in: PubMed
      449. Carroll PR, Presti JC, Small E, Roach M. Focal therapy for prostate cancer 1996: maximizing outcome. Urology. 1997 Mar; 49(3A Suppl):84-94.
        View in: PubMed
      450. Stoller ML, Gentle DL, McDonald MW, Reese JH, Tacker JR, Carroll PR, Best C. Endoscopic management of upper tract urothelial tumors. Tech Urol. 1997; 3(3):152-7.
        View in: PubMed
      451. Friedman GD, Carroll PR, Cattolica EV, Hiatt RA. Can hematuria be a predictor as well as a symptom or sign of bladder cancer? Cancer Epidemiol Biomarkers Prev. 1996 Dec; 5(12):993-6.
        View in: PubMed
      452. Presti JC, Hricak H, Shinohara K, Carroll PR. Prediction of focal extracapsular extension at radical prostatectomy: Relative merit of transrectal ultrasound, endorectal magnetic resonance imaging, prostate specific antigen, prostate specific antigen density, and systematic biopsy. Urol Oncol. 1996 Nov-Dec; 2(6):177-83.
        View in: PubMed
      453. Lubeck DP, Litwin MS, Henning JM, Stier DM, Mazonson P, Fisk R, Carroll PR. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 1996 Nov; 48(5):773-7.
        View in: PubMed
      454. Connolly JA, Shinohara K, Presti JC, Carroll PR. Should cryosurgery be considered a therapeutic option in localized prostate cancer? Urol Clin North Am. 1996 Nov; 23(4):623-31.
        View in: PubMed
      455. Presti JC, Hovey R, Carroll PR, Shinohara K. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate. J Urol. 1996 Nov; 156(5):1685-90.
        View in: PubMed
      456. Small EJ, Fippin LJ, Ernest ML, Carroll PR. A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer. 1996 Oct 15; 78(8):1775-80.
        View in: PubMed
      457. Parivar F, Hricak H, Shinohara K, Kurhanewicz J, Vigneron DB, Nelson SJ, Carroll PR. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology. 1996 Oct; 48(4):594-9.
        View in: PubMed
      458. Seltzer MA, Shinohara K, Bhargava V, Carroll PR, Presti JC. Comparison of systematic sextant and lesion directed biopsies in prostate cancer detection. Urol Oncol. 1996 Sep-Oct; 2(5):136-8.
        View in: PubMed
      459. Presti JC, Carroll PR. Use of prostate-specific antigen (PSA) and PSA density in the detection of stage T1 carcinoma of the prostate. Semin Urol Oncol. 1996 Aug; 14(3):134-8.
        View in: PubMed
      460. Kurhanewicz J, Vigneron DB, Hricak H, Parivar F, Nelson SJ, Shinohara K, Carroll PR. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology. 1996 Aug; 200(2):489-96.
        View in: PubMed
      461. Sarosdy MF, Pisters LL, Carroll PR, Benson MC, Moon TD, Lamm DL, Hudson MA, Lerner SP, Koch MO, Schellhammer PF. Bropirimine immunotherapy of upper urinary tract carcinoma in situ. Urology. 1996 Jul; 48(1):28-32.
        View in: PubMed
      462. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 1996 Jul 1; 56(13):3091-102.
        View in: PubMed
      463. Shinohara K, Connolly JA, Presti JC, Carroll PR. Cryosurgical treatment of localized prostate cancer (stages T1 to T4): preliminary results. J Urol. 1996 Jul; 156(1):115-20; discussion 120-1.
        View in: PubMed
      464. Chen M, Hricak H, Kalbhen CL, Kurhanewicz J, Vigneron DB, Weiss JM, Carroll PR. Hormonal ablation of prostatic cancer: effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging. AJR Am J Roentgenol. 1996 May; 166(5):1157-63.
        View in: PubMed
      465. Cher ML, Stephenson RA, James BC, Carroll PR. Cellular proliferative fraction of metastatic lymph nodes predicts survival in stage D1 (TxN+M0) prostate cancer. J Urol. 1996 May; 155(5):1674-7.
        View in: PubMed
      466. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology. 1996 Mar; 198(3):795-805.
        View in: PubMed
      467. Kalbhen CL, Hricak H, Shinohara K, Chen M, Parivar F, Kurhanewicz J, Vigneron DB, Carroll PR. Prostate carcinoma: MR imaging findings after cryosurgery. Radiology. 1996 Mar; 198(3):807-11.
        View in: PubMed
      468. Connolly JA, Shinohara K, Presti JC, Carroll PR. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology. 1996 Feb; 47(2):225-31.
        View in: PubMed
      469. Presti JC, Hricak H, Narayan PA, Shinohara K, White S, Carroll PR. Local staging of prostatic carcinoma: comparison of transrectal sonography and endorectal MR imaging. AJR Am J Roentgenol. 1996 Jan; 166(1):103-8.
        View in: PubMed
      470. Lue TF, Gleason CA, Brock GB, Carroll PR, Tanagho EA. Intraoperative electrostimulation of the cavernous nerve: technique, results and limitations. J Urol. 1995 Oct; 154(4):1426-8.
        View in: PubMed
      471. Aboseif S, Shinohara K, Weidner N, Narayan P, Carroll PR. The significance of prostatic intra-epithelial neoplasia. Br J Urol. 1995 Sep; 76(3):355-9.
        View in: PubMed
      472. Jaeger TM, Weidner N, Chew K, Moore DH, Kerschmann RL, Waldman FM, Carroll PR. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol. 1995 Jul; 154(1):69-71.
        View in: PubMed
      473. Wolf JS, Carroll PR, Stoller ML. Cost-effectiveness v patient preference in the choice of treatment for distal ureteral calculi: a literature-based decision analysis. J Endourol. 1995 Jun; 9(3):243-8.
        View in: PubMed
      474. Connolly JA, Presti JC, Carroll PR. Anterior bladder neck tube reconstruction at radical prostatectomy preserves functional urethral length--a comparative urodynamic study. Br J Urol. 1995 Jun; 75(6):766-70.
        View in: PubMed
      475. Cher ML, Shinohara K, Breslin S, Vapnek J, Carroll PR. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer. Br J Urol. 1995 Jun; 75(6):771-7.
        View in: PubMed
      476. White S, Hricak H, Forstner R, Kurhanewicz J, Vigneron DB, Zaloudek CJ, Weiss JM, Narayan P, Carroll PR. Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. Radiology. 1995 May; 195(2):385-90.
        View in: PubMed
      477. Sauter G, Carroll P, Moch H, Kallioniemi A, Kerschmann R, Narayan P, Mihatsch MJ, Waldman FM. c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization. Am J Pathol. 1995 May; 146(5):1131-9.
        View in: PubMed PMC1869279
      478. Sauter G, Moch H, Carroll P, Kerschmann R, Mihatsch MJ, Waldman FM. Chromosome-9 loss detected by fluorescence in situ hybridization in bladder cancer. Int J Cancer. 1995 Apr 21; 64(2):99-103.
        View in: PubMed
      479. Peier AM, Meloni AM, Sandberg AA, Leong SP, Carroll PR. Cytogenetic findings in a metastatic renal cell carcinoma. Cancer Genet Cytogenet. 1995 Apr; 80(2):168-9.
        View in: PubMed
      480. Marks LB, Carroll PR, Dugan TC, Anscher MS. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys. 1995 Mar 30; 31(5):1257-80.
        View in: PubMed
      481. Wolf JS, Cher M, Dall'era M, Presti JC, Hricak H, Carroll PR. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol. 1995 Mar; 153(3 Pt 2):993-9.
        View in: PubMed
      482. Cher ML, Carroll PR. Screening for prostate cancer. West J Med. 1995 Mar; 162(3):235-42.
        View in: PubMed PMC1022708
      483. Nguyen HT, Carroll PR. Blunt renal trauma: renal preservation through careful staging and selective surgery. Semin Urol. 1995 Feb; 13(1):83-9.
        View in: PubMed
      484. Cher ML, Chew K, Rosenau W, Carroll PR. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate. 1995 Feb; 26(2):87-93.
        View in: PubMed
      485. Cher ML, Ito T, Weidner N, Carroll PR, Jensen RH. Mapping of regions of physical deletion on chromosome 16q in prostate cancer cells by fluorescence in situ hybridization (FISH). J Urol. 1995 Jan; 153(1):249-54.
        View in: PubMed
      486. Hricak H, White S, Vigneron D, Kurhanewicz J, Kosco A, Levin D, Weiss J, Narayan P, Carroll PR. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal--pelvic phased-array coils. Radiology. 1994 Dec; 193(3):703-9.
        View in: PubMed
      487. Phan CN, Wilkinson M, Cohen MB, Dunn S, Carroll P. Primary osteogenic sarcoma of the urinary bladder successfully treated with combination therapy. Urology. 1994 Nov; 44(5):771-4.
        View in: PubMed
      488. Kim B, Semelka RC, Ascher SM, Chalpin DB, Carroll PR, Hricak H. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology. 1994 Oct; 193(1):239-45.
        View in: PubMed
      489. Wolf JS, Brock GB, Gleason CA, Zvara P, Lue TF, Carroll PR. Laparoscopically implantable nerve-stimulating electrode (LINSE): application to the cavernous nerve in acute and chronic canine models. J Endourol. 1994 Oct; 8(5):375-8.
        View in: PubMed
      490. Chen BJ, Carroll P, Samson L. The Escherichia coli AlkB protein protects human cells against alkylation-induced toxicity. J Bacteriol. 1994 Oct; 176(20):6255-61.
        View in: PubMed PMC196966
      491. Diaz A, Roach M, Marquez C, Coleman L, Pickett B, Wolfe JS, Carroll P, Narayan P. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994 Sep 30; 30(2):323-9.
        View in: PubMed
      492. Shinohara K, Wolf JS, Narayan P, Carroll PR. Comparison of prostate specific antigen with prostate specific antigen density for 3 clinical applications. J Urol. 1994 Jul; 152(1):120-3.
        View in: PubMed
      493. Small EJ, Frye JW, Wilkinson MJ, Carroll PR, Ernest ML, Stagg RJ. A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma. Cancer. 1994 Jun 1; 73(11):2803-7.
        View in: PubMed
      494. Carroll PR. Laparoscopic urological surgery: differentiating what should be done from what can be done. J Urol. 1994 Jun; 151(6):1603-4.
        View in: PubMed
      495. Sauter G, Haley J, Chew K, Kerschmann R, Moore D, Carroll P, Moch H, Gudat F, Mihatsch MJ, Waldman F. Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int J Cancer. 1994 May 15; 57(4):508-14.
        View in: PubMed
      496. Carroll PR, McAninch JW, Wong A, Wolf JS, Newton C. Outcome after temporary vascular occlusion for the management of renal trauma. J Urol. 1994 May; 151(5):1171-3.
        View in: PubMed
      497. Narayan P, Lowe BA, Carroll PR, Thompson IM. Neoadjuvant hormonal therapy and radical prostatectomy for clinical stage C carcinoma of the prostate. Br J Urol. 1994 May; 73(5):544-8.
        View in: PubMed
      498. Sauter G, Deng G, Moch H, Kerschmann R, Matsumura K, De Vries S, George T, Fuentes J, Carroll P, Mihatsch MJ, et al. Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization. Am J Pathol. 1994 Apr; 144(4):756-66.
        View in: PubMed PMC1887234
      499. Carroll PR. Watchful waiting for localized prostate cancer. West J Med. 1994 Mar; 160(3):249.
        View in: PubMed PMC1022391
      500. Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology. 1994 Mar; 43(3):408-10.
        View in: PubMed
      501. Cher ML, Carroll PR. Screening for prostate cancer. West J Med. 1994 Mar; 160(3):250.
        View in: PubMed PMC1022392
      502. Wolf JS, Aronson FR, Small EJ, Carroll PR. Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens. J Surg Oncol. 1994 Jan; 55(1):7-13.
        View in: PubMed
      503. Vapnek JM, Hricak H, Shinohara K, Popovich M, Carroll P. Staging accuracy of magnetic resonance imaging versus transrectal ultrasound in stages A and B prostatic cancer. Urol Int. 1994; 53(4):191-5.
        View in: PubMed
      504. Roach M, Marquez C, Yuo HS, Narayan P, Coleman L, Nseyo UO, Navvab Z, Carroll PR. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994 Jan 1; 28(1):33-7.
        View in: PubMed
      505. Gómez RG, McAninch JW, Carroll PR. Adrenal gland trauma: diagnosis and management. J Trauma. 1993 Dec; 35(6):870-4.
        View in: PubMed
      506. Wolf JS, Shinohara K, Kerlikowske KM, Narayan P, Stoller ML, Carroll PR. Selection of patients for laparoscopic pelvic lymphadenectomy prior to radical prostatectomy: a decision analysis. Urology. 1993 Dec; 42(6):680-8.
        View in: PubMed
      507. Stoller ML, Irby PB, Osman M, Carroll PR. Laparoscopic marsupialization of a simple renal cyst. J Urol. 1993 Nov; 150(5 Pt 1):1486-8.
        View in: PubMed
      508. Ingerman A, Broderick G, Williams RD, Carroll PR. Negative repeat transurethral resection of prostate fails to identify patients with stage A1 prostatic carcinoma at lower risk of progression: a long-term study. Urology. 1993 Nov; 42(5):528-32.
        View in: PubMed
      509. Carroll P, Sendtner M, Meyer M, Thoenen H. Rat ciliary neurotrophic factor (CNTF): gene structure and regulation of mRNA levels in glial cell cultures. Glia. 1993 Nov; 9(3):176-87.
        View in: PubMed
      510. Abu-Elmagd K, Van Thiel DH, Jegasothy BV, Jacobs JC, Carroll P, Rodriquez-Rilo H, Ackerman CD, Fung JJ, Starzl TE. Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506). Ann Intern Med. 1993 Oct 1; 119(7 Pt 1):595-8.
        View in: PubMed PMC3091479
      511. Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE. Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression. Transplant Proc. 1993 Aug; 25(4):2433-4.
        View in: PubMed PMC2981169
      512. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993 Aug; 143(2):401-9.
        View in: PubMed PMC1887042
      513. Wolf JS, Shinohara K, Carroll PR, Narayan P. Combined role of transrectal ultrasonography, Gleason score, and prostate-specific antigen in predicting organ-confined prostate cancer. Urology. 1993 Aug; 42(2):131-7.
        View in: PubMed
      514. McAninch JW, Carroll PR, Armenakas NA, Lee P. Renal gunshot wounds: methods of salvage and reconstruction. J Trauma. 1993 Aug; 35(2):279-83; discussion 283-4.
        View in: PubMed
      515. Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE. Serum cholesterol levels in African Americans after renal transplantation under FK 506 immunosuppression. Transplant Proc. 1993 Aug; 25(4):2435.
        View in: PubMed PMC2978522
      516. Cohen MB, Waldman FM, Carroll PR, Kerschmann R, Chew K, Mayall BH. Comparison of five histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder. Hum Pathol. 1993 Jul; 24(7):772-8.
        View in: PubMed
      517. Wilkinson MJ, Frye JW, Small EJ, Venook AP, Carroll PR, Ernest ML, Stagg RJ. A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma. Cancer. 1993 Jun 1; 71(11):3601-4.
        View in: PubMed
      518. Sauter G, Moch H, Moore D, Carroll P, Kerschmann R, Chew K, Mihatsch MJ, Gudat F, Waldman F. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res. 1993 May 15; 53(10 Suppl):2199-203.
        View in: PubMed
      519. Foster LS, Jajodia P, Fournier G, Shinohara K, Carroll P, Narayan P. The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol. 1993 May; 149(5):1024-8.
        View in: PubMed
      520. Presti JC, Herr HW, Carroll PR. Fertility and testis cancer. Urol Clin North Am. 1993 Feb; 20(1):173-9.
        View in: PubMed
      521. Carroll PR, Waldman FM, Rosenau W, Cohen MB, Vapnek JM, Fong P, Narayan P, Mayall BH. Cell proliferation in prostatic adenocarcinoma: in vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression. J Urol. 1993 Feb; 149(2):403-7.
        View in: PubMed
      522. Waldman FM, Carroll PR, Cohen MB, Kerschmann R, Chew K, Mayall BH. 5-Bromodeoxyuridine incorporation and PCNA expression as measures of cell proliferation in transitional cell carcinoma of the urinary bladder. Mod Pathol. 1993 Jan; 6(1):20-4.
        View in: PubMed
      523. Gasparini ME, Hinman F, Presti JC, Schmidt RA, Carroll PR. Continence after radical cystoprostatectomy and total bladder replacement: a urodynamic analysis. J Urol. 1992 Dec; 148(6):1861-4.
        View in: PubMed
      524. Hricak H, Carroll P. Determination of prostate volume with transrectal ultrasound for cancer screening. Part I. Comparison with prostate specific antigen assays. Invest Radiol. 1992 Sep; 27(9):751-3.
        View in: PubMed
      525. Carroll PR, Presti JC. Comparison of plicated and stapled continent ileocecal stoma. Urology. 1992 Aug; 40(2):107-9.
        View in: PubMed
      526. Vapnek JM, Hricak H, Carroll PR. Recent advances in imaging studies for staging of penile and urethral carcinoma. Urol Clin North Am. 1992 May; 19(2):257-66.
        View in: PubMed
      527. Carroll PR, Dixon CM. Surgical anatomy of the male and female urethra. Urol Clin North Am. 1992 May; 19(2):339-46.
        View in: PubMed
      528. Carroll PR, Sugimura K, Cohen MB, Hricak H. Detection and staging of prostatic carcinoma after transurethral resection or open enucleation of the prostate: accuracy of magnetic resonance imaging. J Urol. 1992 Feb; 147(2):402-6.
        View in: PubMed
      529. Myneni L, Hricak H, Carroll PR. Magnetic resonance imaging of renal carcinoma with extension into the vena cava: staging accuracy and recent advances. Br J Urol. 1991 Dec; 68(6):571-8.
        View in: PubMed
      530. Wolf JS, Carroll PR. Bilateral renal oncocytomas: management and nuclear analysis. J Surg Oncol. 1991 Dec; 48(4):272-6.
        View in: PubMed
      531. Gasparini M, Carroll P, Stoller M. Palliative percutaneous and endoscopic urinary diversion for malignant ureteral obstruction. Urology. 1991 Nov; 38(5):408-12.
        View in: PubMed
      532. Presti JC, Carroll PR. Bilateral spontaneous renal hemorrhage due to polyarteritis nodosa. West J Med. 1991 Nov; 155(5):527-8.
        View in: PubMed PMC1003079
      533. Vapnek JM, Quivey JM, Carroll PR. Acquired immunodeficiency syndrome-related Kaposi's sarcoma of the male genitalia: management with radiation therapy. J Urol. 1991 Aug; 146(2):333-6.
        View in: PubMed
      534. Waldman FM, Carroll PR, Kerschmann R, Cohen MB, Field FG, Mayall BH. Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res. 1991 Jul 15; 51(14):3807-13.
        View in: PubMed
      535. McAninch JW, Carroll PR, Klosterman PW, Dixon CM, Greenblatt MN. Renal reconstruction after injury. J Urol. 1991 May; 145(5):932-7.
        View in: PubMed
      536. Semelka RC, Hricak H, Stevens SK, Finegold R, Tomei E, Carroll PR. Combined gadolinium-enhanced and fat-saturation MR imaging of renal masses. Radiology. 1991 Mar; 178(3):803-9.
        View in: PubMed
      537. Carroll PR, McAninch JW. Use of the ileocecal segment for bladder substitution or continent urinary diversion. Urol Int. 1991; 46(3):283-9.
        View in: PubMed
      538. McAninch JW, Dixon CM, Carroll PR. [The surgical treatment of renal trauma]. Vestn Khir Im I I Grek. 1990 Nov; 145(11):64-72.
        View in: PubMed
      539. Wilkinson M, Carroll PR. Testicular carcinoma in patients positive and at risk for human immunodeficiency virus. J Urol. 1990 Nov; 144(5):1157-9.
        View in: PubMed
      540. Baskin LS, Dixon C, Stoller ML, Carroll PR. Pyoderma gangrenosum presenting as Fournier's gangrene. J Urol. 1990 Oct; 144(4):984-6.
        View in: PubMed
      541. Baskin LS, Carroll PR, Cattolica EV, McAninch JW. Necrotising soft tissue infections of the perineum and genitalia. Bacteriology, treatment and risk assessment. Br J Urol. 1990 May; 65(5):524-9.
        View in: PubMed
      542. Presti JC, Schmidt RA, Narayan PA, Carroll PR, Tanagho EA. Pathophysiology of urinary incontinence after radical prostatectomy. J Urol. 1990 May; 143(5):975-8.
        View in: PubMed
      543. Carroll PR, McAninch JW, Klosterman P, Greenblatt M. Renovascular trauma: risk assessment, surgical management, and outcome. J Trauma. 1990 May; 30(5):547-52; discussion 553-4.
        View in: PubMed
      544. Carroll PR, Presti JC, McAninch JW, Tanagho EA. Functional characteristics of the continent ileocecal urinary reservoir: mechanisms of urinary continence. J Urol. 1989 Oct; 142(4):1032-6.
        View in: PubMed
      545. McAninch JW, Carroll PR. Renal exploration after trauma. Indications and reconstructive techniques. Urol Clin North Am. 1989 May; 16(2):203-12.
        View in: PubMed
      546. Mee SL, McAninch JW, Robinson AL, Auerbach PS, Carroll PR. Radiographic assessment of renal trauma: a 10-year prospective study of patient selection. J Urol. 1989 May; 141(5):1095-8.
        View in: PubMed
      547. Carroll PR, McAninch JW. Staging of renal trauma. Urol Clin North Am. 1989 May; 16(2):193-201.
        View in: PubMed
      548. Carroll PR, Klosterman P, McAninch JW. Early vascular control for renal trauma: a critical review. J Urol. 1989 Apr; 141(4):826-9.
        View in: PubMed
      549. Baskin L, Mee S, Matthay M, Carroll PR. Ureteral obstruction caused by vasculitis. J Urol. 1989 Apr; 141(4):933-5.
        View in: PubMed
      550. Presti JC, Carroll PR, McAninch JW. Ureteral and renal pelvic injuries from external trauma: diagnosis and management. J Trauma. 1989 Mar; 29(3):370-4.
        View in: PubMed
      551. Lue TF, Carroll PR, Moore C. Treatment of impotence in cancer patients. Important Adv Oncol. 1989; 193-203.
        View in: PubMed
      552. Carroll PR, Narayan P. Treatment options for hormone-insensitive or independent prostatic carcinoma. Semin Urol. 1988 Nov; 6(4):322-35.
        View in: PubMed
      553. Carroll PR, Klosterman PW, McAninch JW. Surgical management of renal trauma: analysis of risk factors, technique, and outcome. J Trauma. 1988 Jul; 28(7):1071-7.
        View in: PubMed
      554. Thurnher S, Hricak H, Carroll PR, Pobiel RS, Filly RA. Imaging the testis: comparison between MR imaging and US. Radiology. 1988 Jun; 167(3):631-6.
        View in: PubMed
      555. Rebeck GW, Coons S, Carroll P, Samson L. A second DNA methyltransferase repair enzyme in Escherichia coli. Proc Natl Acad Sci U S A. 1988 May; 85(9):3039-43.
        View in: PubMed PMC280138
      556. Bernstein SA, Reuter VE, Carroll PR, Whitmore WF. Primary signet-ring cell carcinoma of urinary bladder. Urology. 1988 May; 31(5):432-6.
        View in: PubMed
      557. Hricak H, Thoeni RF, Carroll PR, Demas BE, Marotti M, Tanagho EA. Detection and staging of renal neoplasms: a reassessment of MR imaging. Radiology. 1988 Mar; 166(3):643-9.
        View in: PubMed
      558. Carroll PR, Morse MJ, Koduru PP, Chaganti RS. Testicular germ cell tumor in patient with Klinefelter syndrome. Urology. 1988 Jan; 31(1):72-4.
        View in: PubMed
      559. Carroll PR, Whitmore WF, Richardson M, Bajorunas D, Herr HW, Williams RD, Fair WR, Chaganti RS. Testicular failure in patients with extragonadal germ cell tumors. Cancer. 1987 Jul 1; 60(1):108-13.
        View in: PubMed
      560. Carroll PR, Morse MJ, Whitmore WF, Sogani PC, Klotz L, Herr HW, Fair WR, Feldshuh R, Chaganti RS. Fertility status of patients with clinical stage I testis tumors on a surveillance protocol. J Urol. 1987 Jul; 138(1):70-2.
        View in: PubMed
      561. Carroll PR, Murty VV, Reuter V, Jhanwar S, Fair WR, Whitmore WF, Chaganti RS. Abnormalities at chromosome region 3p12-14 characterize clear cell renal carcinoma. Cancer Genet Cytogenet. 1987 Jun; 26(2):253-9.
        View in: PubMed
      562. Carroll PR, Whitmore WF, Herr HW, Morse MJ, Sogani PC, Bajorunas D, Fair WR, Chaganti RS. Endocrine and exocrine profiles of men with testicular tumors before orchiectomy. J Urol. 1987 Mar; 137(3):420-3.
        View in: PubMed
      563. Carroll PR, Cattolica EV, Turzan CW, McAninch JW. Necrotizing soft-tissue infections of the perineum and genitalia. Etiology and early reconstruction. West J Med. 1986 Feb; 144(2):174-8.
        View in: PubMed PMC1306554
      564. Bretan PN, Carroll PR, McClure RD, Williams RD. Improved continuous flow transurethral prostatectomy. J Urol. 1985 Jul; 134(1):77-80.
        View in: PubMed
      565. Carroll PR, McAninch JW. Operative indications in penetrating renal trauma. J Trauma. 1985 Jul; 25(7):587-93.
        View in: PubMed
      566. Carroll PR, Leitner TC, Yen TS, Watson RA, Williams RD. Incidental carcinoma of the prostate: significance of staging transurethral resection. J Urol. 1985 May; 133(5):811-4.
        View in: PubMed
      567. Nicolaisen GS, McAninch JW, Marshall GA, Bluth RF, Carroll PR. Renal trauma: re-evaluation of the indications for radiographic assessment. J Urol. 1985 Feb; 133(2):183-7.
        View in: PubMed
      568. Carroll PR, Lue TF, Schmidt RA, Trengrove-Jones G, McAninch JW. Penile replantation: current concepts. J Urol. 1985 Feb; 133(2):281-5.
        View in: PubMed
      569. Carroll PR, Williams RD, Kim MJ, Dombrovskis S. Mitomycin C reused: an in vitro cost-effectiveness study. J Urol. 1984 Sep; 132(3):583-6.
        View in: PubMed
      570. Carroll PR, McAninch JW. Major bladder trauma: mechanisms of injury and a unified method of diagnosis and repair. J Urol. 1984 Aug; 132(2):254-7.
        View in: PubMed
      571. Carroll PR, McAninch JW. Major bladder trauma: the accuracy of cystography. J Urol. 1983 Nov; 130(5):887-8.
        View in: PubMed
      572. Carroll PR, Pellegrini C, Hedgcock MW, Stein R, Williams RD. Microscopic hematuria, left renal mass with renal vein obstruction and elevated serum level of carcinoembryonic antigen in a 56-year-old man. J Urol. 1983 Mar; 129(3):568-73.
        View in: PubMed
      573. McAninch JW, Carroll PR. Renal trauma: kidney preservation through improved vascular control-a refined approach. J Trauma. 1982 Apr; 22(4):285-90.
        View in: PubMed
      574. Willis AJ, Huang AH, Carroll P. Primary melanoma of the bladder: a case report and review. J Urol. 1980 Feb; 123(2):278-81.
        View in: PubMed
      575. BAKER R, CARROLL P, HAYES D. SIGMOID SEGMENT FOR BLADDER SUBSTITUTE AFTER TOTAL OR SUBTOTAL CYSTECTOMY. J Urol. 1963 Sep; 90:289-95.
        View in: PubMed
      Peter's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP